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 ABSTRACT 
Intensity Modulated Radiation Therapy (IMRT) is a modern technique of delivering radiation 
treatments to cancer patients. In IMRT technology, intensities must be chosen for the many small 
unit grids into which the beams are divided to produce a desired distribution of dose at points 
throughout the body with the goal of maximizing dose delivered to the tumor while sparing 
healthy tissues from excessive radiation and keeping dose homogeneous across the tumor.  
Although IMRT plans are optimized as a single overall treatment plan, they are delivered over 
30-50 treatment sessions (fractions) and both cumulative and per-fraction dose constraints apply.  
 
The extended time period of treatment allows for periodic re-imaging of the changing tumor 
geometry and for adapting the treatment plan accordingly. This research presents promising 
iterative optimization approaches that re-optimize and update the treatment plans periodically by 
incorporating the latest tumor geometry information. Two realistic lung cases simulating 
practice, based on anonymized archive datasets, are used to test the effectiveness of the proposed 
adaptive planning approaches. The computed optimal plans both satisfy cumulative and per-
session dose constraints while improving the objective (average tumor dose) as compared to non-
adaptive treatment. 
 
In addition to tracking tumor geometrical changes through the treatment, recent advances in 
imaging technology also provide more insight on tumor biology which has been traditionally 
disregarded in planning. The current practice of delivering homogeneous physical dose 
distributions across the tumor can be improved by nonhomogeneous distributions guided by the 
biological responses of the tumor points. This research is one of the first efforts in developing 
 radiation therapy planning optimization methods with tumor biology information while 
maintaining both cumulative and per-fraction dose constraints. The proposed biological 
optimization models generate treatment plans reacting to the tumor biology prior to the treatment 
as well as the changing tumor biology throughout the treatment. The optimization models are 
tested on a simulated head and neck test case. Results show computed biologically optimized 
plans improve on tumor control obtained by traditional plans ignoring biology, and also with 
adaptive over non-adaptive methods.  
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1 
1 Introduction 
According to the American Cancer Society, “Cancer is the second most common cause of death 
in the US, exceeded only by heart disease, and cancer accounts for nearly 1 of every 4 deaths”. 
In 2011, over 570,000 Americans are expected to die of cancer, more than 1,500 people a day, 
and the new cases that are expected to be diagnosed are about 1.6 million (Cancer Facts 
&Figures, 2011). Treatment methods to cure cancer include surgery, radiation therapy, 
chemotherapy, hormone therapy, biological therapy, and targeted therapy. Radiation therapy can 
be used alone or in combination with other treatment methods. Over half of all cancer patients 
receive radiation therapy at some point during their treatment (Bortfeld et al., 2008). 
 
1.1 IMRT Technology 
Radiation therapy aims to destroy cancer cells or slow their rate of growth by using high energy 
rays without exposing the healthy tissues to excess dose. When applying radiation therapy to a 
patient, a device mounted on a gantry called a linear accelerator rotates around the patient and 
shoots radiation from different beam angles aiming at targets (Figure 1.1). Using different beam 
angles helps better sparing the healthy tissues since a particular surrounding healthy tissue will 
not be heavily exposed to radiation consistently.  
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4 
requirements, dose maxima on healthy tissues, dose-volume limits of protected fractions of 
healthy tissues (both a maximum limit and a lesser dose threshold that a certain percentage of the 
healthy tissue can receive), and the minimum dose limits on secondary targets.  
 
Although IMRT is planned as a single overall treatment, it is delivered over several weeks in a 
series of fractions or treatment sessions. In order to have more effective and applicable treatment 
plans, both cumulative and per-fraction dose constraints need to be taken into consideration (Wu 
et al., 2000; Blanco and Chao, 2002). Table 1.1 shows a prescription for one of the lung cases 
used in this research. The table presents both cumulative and per-fraction (fraction size) dose 
objectives/limits for targets and healthy tissues in the prescription. For healthy tissues subject to 
dose-volume constraints, a mean dose limit based on a predictive model discovered in Europe 
and confirmed in the US that reduces the combinatorial complexity of planning (Kwa et al., 
1998; Bradley et al., 2007) is used. This predictive model using mean lung dose has been shown 
to be a good predictor for radiation pneumonitis (frequent complication with symptoms of cough, 
fever, and shortness of breath found typically within 6 months after the start of radiotherapy) 
based on analysis of multiple datasets from different institutions which underlines the use of 
mean dose limits in the prescriptions. 
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Table 1.1: Prescription for the Lung Case Illustrating Both Cumulative and Fraction Size Dose 
Objectives/Limits 
 
Structure 
 
Structure 
Description 
Prescription 
Cumulative Dose 
Objective/Limit  
(Gy) 
Fraction Size 
Dose Limit 
(Gy) 
Tumor Primary Target 
Maximize avg. dose 
≥ 2 
950
dosemax.
dose min. .  
PTV2 Secondary Target 100% ≥ 50 ≥ 2 
Right Lung Healthy Tissue Avg. dose ≤ 17 ≤ 2.1 
Left Lung Healthy Tissue Avg. dose ≤ 17 ≤ 2.1 
Heart Healthy Tissue Avg. dose ≤ 35 ≤ 2.1 
Esophagus  Healthy Tissue Avg. dose ≤ 35 ≤ 2.1 
Not Otherwise Specified 
Tissue 
Healthy 
Tissue 100% ≤ 100 ≤ 2.1 
Spinal Cord Healthy Tissue 100% ≤ 45 ≤ 2.1 
 
Numerous methods have been proposed in the literature to generate radiation therapy plans. Of 
these methods, optimization models using mathematical programming formulations have been 
developed to determine the best beamlet intensities (Langer et al., 1990; Langer et al., 1991; 
Langer et al., 2003; Lee et al., 2003; Romeijn et al., 2003; Romeijn et al., 2006; Preciado-
Walters et al., 2004, Lee et al., 2006; Tuncel, 2008) and the best aperture intensities (Romeijn et 
al., 2005; Preciado-Walters et al., 2006), along with non-linear gradient techniques (Cho et al., 
1998; Hristov and Fallone, 1998; Spirou and Chui, 1998; Wu and Mohan, 2000).  Other methods 
include randomized approaches, such as simulated annealing (Webb, 1991; Morril et al., 1990; 
6 
Mageras and Mohan, 1993; Langer et al., 1996) and genetic algorithms (Langer et al., 1996; 
Ezzel, 1996; Wu et al., 2000). 
 
1.3 Objectives of the Research 
All of these available methods used to generate radiation therapy plans optimize a single 
cumulative treatment plan and neglect changes in the tumor geometry over time. However, with 
the recent advances in imaging technology, the Image Guided Radiation Therapy (IGRT) allows 
acquiring images throughout the treatment that capture the changes in the tumor geometry. This 
motivates devising adaptive optimization methodologies that re-optimize the treatment plan in 
response to the changing tumor geometry while maintaining both cumulative and fraction size 
dose constraints. 
 
In addition, the recent molecular and functional imaging technology can provide more insight on 
the tumor biology and help incorporating the biological information, which has traditionally been 
unknown, into the treatment planning. The ability to understand the tumor biology and quantify 
the biological information invites developing optimization methodologies that would adjust 
IMRT plans by incorporating tumor biology information in order to achieve more effective 
treatment plans. 
 
This dissertation research develops optimization models to meet the demand for optimization 
methodologies exploiting tumor geometry and biology information over the course of the 
treatment. The objectives of this dissertation research are as follows. 
7 
 To deal with both cumulative and fractionation constraints in adaptive IMRT planning 
optimization 
 To develop, implement, and test adaptive optimization methodologies that re-optimize 
the treatment plan in response to the changes in the tumor geometry while satisfying both 
cumulative and fractionation dose constraints to achieve the best IMRT design for the 
overall treatment and for each fraction 
 To develop, implement, and test static and adaptive optimization models that include the 
initial and changing tumor biology information into the optimization which helps 
adjusting IMRT plans to the tumor sensitivity in order to yield more effective treatment 
plans 
 
1.4 Research Tools 
The optimization models and methodologies developed in this dissertation research are 
implemented in C++ programming language by using ILOG Concert Technology Library. The 
formulations are solved by using CPLEX 11.2 software. Since the cuts generated by CPLEX do 
not help the optimization process, that feature of CPLEX is turned off. The other CPLEX 
parameters are kept at their default values. All the computational experiments are performed on 
the Industrial Engineering Department’s Windows Server 2003 R2 Datacenter x64 Edition 
having 128 GB RAM and 16 processors at 2.93 GHz. The best performance is achieved by 
allocating single processor.   
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1.5 Dissertation Organization 
This dissertation is organized as follows. Chapter 2 derives mathematical programming and 
related methods that optimize treatment plans where both cumulative and fraction size dose 
limits on each tissue are satisfied. Chapter 3 describes the fractionation challenge that is 
magnified in adaptive IMRT planning. Chapter 4 addresses the solution approaches for the 
fractionation challenge in adaptive IMRT by developing an adaptive planning optimization 
methodology with changing tumor geometry and fraction size limits and presents the 
computational experiments showing the benefit of adaptation. Biologically guided IMRT 
optimization methodologies are presented in Chapter 5 as well as the results demonstrating the 
improvements in the treatment outcomes. Finally, conclusions, contributions and future research 
are given in Chapter 6.   
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2 Models for Optimization of Treatment Plans Satisfying Fraction Size Requirements 
2.1 Description of the CERRLung Test Case 
This section describes one of the lung test cases, referred as “CERRLung”, which is used in the 
computational experiments presented in Chapter 2 and 4. Table 2.1 shows the volume (cm3), 
number of sampling voxels used for the optimization, the size of each voxel (cm3/voxel), and the 
influence matrix density for each structure in the lung test case. The influence matrix represents 
all the voxels as its rows and all selected beamlets as its columns and each element of the matrix 
(dose coefficient) defines dose per unit beamlet intensity. The influence matrix density (%) for a 
structure indicates the ratio of its non-zero dose coefficients to its all dose coefficients in the 
influence matrix. The influence matrix for this test case is generated using a sample case found 
on the CERR website (“CERR: A Computational Environment for Radiotherapy Research”) 
established to allow collaborative computational experimentation in radiation therapy. The 
prescription for this test case is presented in Section 1.2.  
 
Table 2.1: Description of the Lung Test Case 
Structure Structure Description 
Volume 
(cm3) 
Number of 
Sampling 
Voxels Used 
for 
Optimization
cm3/Voxel in 
Optimization 
The 
Influence 
Matrix 
Density 
Tumor Primary Target 90.6 2,133 0.04 94% 
PTV2 Secondary Target 256.0 1,519 0.17 93%
Right Lung Healthy Tissue 1,893.2 2,805 0.67 76%
Left Lung Healthy Tissue 1,689.3 2,476 0.68 35%
Heart Healthy Tissue 599.4 876 0.68 44%
Esophagus Healthy Tissue 42.3 233 0.18 66%
Not Otherwise 
Specified Healthy Tissue 31,430.0 11,425 2.75 40% 
Spinal Cord Healthy Tissue 56.2 316 0.18 52% 
Beam Angles: 0 40 80 120 160 200 240 280 320 (780 beamlets) 
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2.2 Notation 
Tissues are represented by a collection of points (voxels).  Let T denote the set of tumor points, S 
denote the set of points in the secondary target and Hk denote the set of points in kth healthy 
tissue for KKk  .  Here, K and K  denote the set of indices for the healthy and dose-volume 
healthy tissues, respectively. 
 
The set of beamlets used from preselected beam angles is denoted by J.  Dose coefficients aij 
denote the dose received by tissue point i per unit intensity of beamlet j. The coefficients for all 
tissues form the influence matrix for the problem as defined above. The dose received from 
beamlet j at point i is jij xa  where 0x j   is the continuous decision variable defined as the value 
of intensity assigned to beamlet j.   
Let variables id  denote the dose received at point i. This research makes the standard 
assumption that the dose can be expressed as a linear combination of the individual beamlet 
intensities. Thus, for every point i,  



Jj
jiji xad                                              (2.1) 
 
Let Dmin be a variable denoting the minimum tumor dose and coefficient   be a homogeneity 
ratio limit with 10   . The prescribed minimum dose for the secondary target is denoted as 
total
secl  whereas the prescribed maximum dose for healthy tissues Kk   is denoted as totalku . The 
parameter k  represents the mean dose limit for the kth dose-volume healthy tissue. 
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The fraction size limits are represented by the following parameters. Let dailytumorl  denote the 
minimum dose that any point in the tumor must receive during the fraction and dailysecl  denote the 
minimum dose any point in the secondary target must receive during the fraction.  dailyku  denotes 
the maximum dose that any point in healthy tissue KKk   can receive during the fraction.  
 
2.3 Optimization against Cumulative Dose Limits Alone 
2.3.1 The Linear Programming (LP) Model 
The LP formulation shown below and presented in Saka et al. (6) in 2010 is used to optimize the 
treatment plan against the cumulative dose limits alone. It maximizes the average tumor dose 
received over the entire treatment (2.2) subject to several overall treatment constraints. 
Constraint set (2.3) ensures that the average dose received across all points in kth dose-volume 
healthy tissue is limited by the corresponding mean limit. Constraint sets (2.4) and (2.5) for the 
overall treatment guarantees that the upper dose limit for healthy tissues and the lower dose limit 
for secondary target tissue are satisfied, respectively. Constraint set (2.6) is the dose consistency 
constraint assuring secondary target doses do not exceed the maximum tumor dose. Constraint 
(2.7) satisfies the tumor dose homogeneity by enforcing the ratio of the minimum and maximum 
tumor doses to be greater than or equal to homogeneity limit a.   
 
T/d
Ti
i 



maximize                        (2.2) 
kk
Hi
i Hd
k


 Kk                     (2.3) 
total
ki ud   kHi,Kk                     (2.4) 
total
seci ld   Si                            (2.5) 
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
min
i
Dd   Si                            (2.6) 

min
imin
DdD    Ti                      (2.7)     
 
2.3.2 Difficulties with Fractionating the Cumulative Plan	
Traditionally, optimized treatment plans are delivered into 30-50 fractions for which fraction 
objectives apply (Wu et al., 2000; Blanco and Chao, 2002). The cumulative tolerances for 
normal tissues are valid only if delivered in doses per fraction no higher than about 2.1 Gy, and 
tumor eradication becomes uncertain when delivered dose per fraction falls below about 1.8 Gy 
(Stewart and Li, 2007). Successful treatment rests on delivering feasible fractions satisfying 
these stated fraction size dose objectives. 
 
The optimized treatment plan cannot be divided into too many fractions since it is required to 
deliver the minimum fraction size dose to the primary and secondary target. This puts an upper 
bound on N denoted as N . Here, N denotes the integer number of fractions the treatment plan 
will be given. N  (not necessarily integer) is determined in the expression (2.8) as by taking the 
minimum of the number of fractions dividing the secondary target doses by the secondary target 
fraction size limit and the number of fractions dividing all the tumor doses by the tumor  fraction 
size dose limit. 








 daily
tumor
min
daily
sec
i
Si l
D,
l
dminminNN                       (2.8)
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On the other hand, the treatment plan cannot be divided into too few fractions, because the 
healthy tissues cannot receive a dose more than their maximum fraction size limits during each 
fraction. This puts a lower bound on N denoted by N  (not necessarily integer) determined in the 
expression (2.9) by taking the maximum of number of fractions dividing the maximum dose each 
healthy tissue receives by its fraction size dose limit. 





 daily
k
i
KKk
,Hi u
dmaxNN
k
                       (2.9) 
 
When the treatment plan is optimized against the cumulative dose limits alone, the lower bound 
N  may be greater than the upper bound N ; therefore, a feasible N to divide the treatment plan 
does not exist. This is demonstrated by the results given in Table 2.2. There, 
  252897250  /.,/minN and 349125103 ../.N  . The treatment plan can be divided at 
most in 25 fractions in order to satisfy the minimum fraction size limit (≥2 Gy) on the targets. On 
the other hand, it must be divided in at least   50349 .  fractions in order not to violate the 
maximum fraction size limit (≤2.1 Gy) on the right lung. As a result, a feasible integer N that 
equally divides the cumulative treatment plan and satisfies both the minimum and maximum 
fraction size dose limits cannot be found.  
 
Furthermore, when the cumulative doses are divided by the integer upper (N=25) or integer 
lower (N=50) bounds, the fraction size dose limits are significantly violated (4.14 Gy > 2.1 Gy 
for the right lung in integer upper bound division, 1.0 < 2.0 Gy for the secondary target PTV2 in 
integer lower bound division). 
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Table 2.2: Optimization against Cumulative Dose Limits Alone 
Dose Statistics 
Cum. 
Dose 
(Gy) 
Fraction 
Size Dose 
Limit (Gy) 
Feasible 
Integer 
Number of 
Fractions (N) 
Fraction Size 
Dose (Gy) 
When   25 NN  
Fraction Size 
Dose (Gy) 
When 
  50 NN  
Min. Tumor 97.8 ≥2 N≤48 3.91 1.96 
Min. PTV2 50.0 ≥2 N≤25 2.00 1.00 
Max. Right Lung 103.5 ≤2.1 N≥50 4.14 2.07 
Notation: N  (not necessarily integer) denotes the maximum number of fractions dividing all the 
targets’ doses by their fraction size limit, and N (not necessarily integer) denotes the minimum 
number of fractions dividing all the healthy tissues’ doses by their fraction size limit. PTV2 
represents the secondary target. 
 
2.4 Ratio Model: Optimization by Including Ratio Constraints and Rescaling 
2.4.1 Ratio-Enforcing Constraints 
In order to find a feasible N to divide the treatment plan, N  needs to be at least less than or equal 
to N . Thus: 


 









 daily
tumor
min
daily
sec
i
Sidaily
k
i
KKk
,Hi l
D,
l
dminminN
u
dmaxN
k
                  (2.10) 
 
Let smin be a variable that defines the minimum dose that the secondary target receives, so
 iSimin dmins  . Rewriting condition (2.10) by using this expression and then rearranging some 
terms gives the condition in (2.11) which states that the ratio of dose at any healthy tissue point 
to the dose at any primary or secondary tumor point cannot exceed the ratio of their respective 
fraction size limits. 
 



 
 daily
tumor
daily
k
mindaily
sec
daily
k
miniHi l
uD,
l
usmindmax
k
                   (2.11) 
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This condition is incorporated into the LP-formulation referenced in the previous section by 
adding ratio constraint sets (2.12) through (2.15) that ensure that the dose distribution healthy 
tissues receive are within a specified ratio of the dose distribution the targets receive. Constraint 
sets (2.12) and (2.13) capture the minimum secondary target and the tumor doses, respectively. 
Constraint sets (2.14) and (2.15) ensure that the maximum dose that each healthy tissue receives 
should be within a ratio of the minimum secondary target dose and the minimum tumor dose, 
respectively. The LP-formulation presented in Section 2.3.1 plus these ratio constraint sets 
constitute the ratio model.    
  mini sd    Si              (2.12) 
  mini Dd    Ti              (2.13) 
  mindaily
sec
daily
k
i s*l
ud    kHi,KKk            (2.14) 
  mindaily
tumor
daily
k
i D*l
ud    kHi,KKk            (2.15) 
 
Table 2.3 shows the results from optimizing the treatment plan for the CERRLung test case by 
solving the ratio model. Based on the dose statistic,   23624742472 ./.,/.minN  and 
2361276 ../N  . However, there is still not an integer N between N  and N . In addition, 
when the cumulative doses are divided by the integer upper (N=36) or integer lower (N=37) 
bounds, the fraction size dose limits are still violated (2.11 Gy > 2.1 Gy for the right lung in 
integer upper bound division, 1.96 < 2.0 Gy for the secondary target PTV2 in integer lower 
bound division).  
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Table 2.3: Optimization including Ratio Constraints 
Dose Statistics 
Cum. 
Dose 
(Gy) 
Fraction 
Size Dose 
Limit 
(Gy) 
Feasible 
Integer 
Number of 
Fractions 
(N) 
Fraction Size 
Dose (Gy) 
When   36 NN  
Fraction Size 
Dose (Gy) 
When 
  37 NN  
Min. Tumor 74.4 ≥2 N≤37 2.07 2.01 
Min. PTV2 72.4 ≥2 N≤36 2.01 1.96 
Max. Right Lung 76.0 ≤2.1 N≥37 2.11 2.05 
Notation: N  (not necessarily integer) denotes the maximum number of fractions dividing all the 
targets’ doses by their fraction size limit, and N (not necessarily integer) denotes the minimum 
number of fractions dividing all the healthy tissues’ doses by their fraction size limit. PTV2 
represents the secondary target. 
 
2.4.2 Re-scaling to Achieve Feasibility 
When N satisfying the integrality condition and    NNN   cannot be found, the dose 
distribution can always be rescaled down on all plan intensities  in order to get an N satisfying 
fraction size limits. 
 
Proposition: It is always possible to find a rescaling factor r* to achieve a feasible division of 
the treatment plans solving the ratio model.  
Proof: Since N  and N  are within an integer bracket, it is always possible to find 10  *r that 
rescales  *r1N   to  N  where   N/N1*r  . Given NN  , rescaling N  by r* and 
rounding it down will give  N . Therefore, by rescaling doses down by   N/N1 , the 
treatment plan can always be divided into  N  feasible fractions. É   
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Note that rescaling doses down may violate the minimum cumulative dose limit on the secondary 
target if dailysec
total
sec l/l  is fractional and the cumulative dose constraint on the secondary target 
(constraint set (2.5)) is active in the optimization implying totalsecmin ls  . In order to avoid this 
violation, one can re-optimize the treatment plan by adding the fraction size dose ( dailysecl ) to the 
minimum cumulative dose limit on that tissue and then rescaling the dose distribution.   
    
The effects of rescaling are demonstrated in Figure 2.1 by using the results in Table 2.3. Figure 
2.1 shows the minimum doses the tumor and secondary target PTV2 receives and the maximum 
dose the right lung receives before and after rescaling. It also displays the bounds on the number 
of fractions to feasibly divide the corresponding doses. In this example, recall that 236.NN  , 
so the treatment plan cannot be divided more than 36 and less than 37 fractions. The rescaling 
factor is computed as r*=0.005=1-(36/36.2). Rescaling the doses down by 0.5% allows treatment 
plan to be divided in 36 fractions.  
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Figure 2.1: Rescaling Dose Distribution Received by Solving the Ratio Model (The bounds on 
the number of fractions into which the doses can be divided without violating fraction size 
requirement are given in the parenthesis. PTV2 represents the secondary target.) 
 
2.5 Uniform Fractionation Model: Optimization Including Integer Fractionation 
Constraints 
A single integer variable mixed-integer linear programming (MILP) model can be developed 
which generates higher quality treatment plans while explicitly satisfying the fraction size dose 
limits. The underlying concepts for this uniform fractionation model were first developed by 
Dink in 2005 and Dink et al. in 2011. The model maximizes the average tumor dose objective 
(2.2) subject to the overall treatment constraint sets (2.3) through (2.7) and the integer 
fractionation constraint sets (2.16) through (2.18) given below. Constraint sets (2.16) through 
(2.18) impose lower dose limits on the secondary target and tumor points, and the upper dose 
limits on all healthy tissue points for the N fractions in the plan. Here, N is an integer variable 
74.4 (≤37.2)
72.4 (≤36.2)
76.0 (≥36.2)
74.1 (≤37)
72.0 (≤36)
75.6 (≥36)
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and defined as the number of fractions in the plan. These integer fractionation constraints ensure 
that the plan can be delivered in N equal, feasible fractions.  
 Nld
daily
seci   Si                    (2.16) 
 Nld dailytumori    Ti                   (2.17) 
 Nud dailyki   kHiKKk  ,                  (2.18) 
 
Figure 2.2 compares the average tumor doses obtained by solving the uniform fractionation 
model and the rescaled solution for the lung test case. The uniform fractionation model improves 
the average tumor dose of 75.9 Gy received from the rescaled solution to 76.2 Gy corresponding 
to a 0.3 Gy increase. These computational results illustrate the mathematical fact that the 
rescaled solution cannot be better than the optimal solution received from the uniform 
fractionation model, because the ratio solution is in the feasible space for the uniform 
fractionation model. In addition to offering the opportunity to produce better solutions, solving 
the uniform fractionation model will yield an optimal fractionation in every case if there is any.    
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Figure 2.2: Rescaled Solution vs. Uniform Fractionation Model Solution (The minimum and 
maximum doses delivered to the tumor are shown with lower and upper bar on the columns, 
respectively.) 
 
Although small in these results, the difference between the rescaled solution and the uniform 
fractionation model solution could worsen as the doses are rescaled down by a higher rescaling 
factor. Table 2.4 shows the highest possible values of   N/Nr 1  for different values of  N . 
In this table, N  is kept very close to   1N  in order to get an upper bound. As this table shows, 
the doses could be rescaled down significantly as the treatment plan is optimized on fewer 
fractions. For instance, for values of   18N ,  the dose distribution could be rescaled down by 
more than 5% possibly causing the solution to perform significantly worse compared to the 
uniform fractionation model solution. As a result, solving the uniform fractionation model can be 
more beneficial when clinical conditions, such as using tighter cumulative dose limits on healthy 
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tissues or using higher fraction size limits, requires the treatment plan to be delivered in fewer 
fractions. 
 
Table 2.4: Highest Possible Values of Re-scaling Factor (r) for Different  N  
 N  N    N/Nr 1
40 40.999 0.024 
30 30.999 0.032 
20 20.999 0.048 
18 18.999 0.053 
10 10.999 0.091 
5 5.999 0.167 
2 2.999 0.333 
Notation: N  (not necessarily integer) denotes the maximum number of fractions dividing all the 
targets’ doses by their fraction size limit, and N (not necessarily integer) denotes the minimum 
number of fractions dividing all the healthy tissues’ doses by their fraction size limit.  
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3 The Fractionation Challenge in Adaptive IMRT Planning 
3.1 Background 
Chapter 2 addressed the challenges that may arise in developing one cumulative plan (with 
secondary targets) and constraining or adjusting it to satisfy per fraction constraints. Still, the 
current standard practice of developing only one cumulative plan (without the secondary targets) 
at the onset of treatment often results in planned dose to primary target higher than that planned 
for any healthy tissue, and the minimum fraction dose for tumor slightly less than that of normal 
tissues.  Then an integer number of equal fractions can easily be chosen to divide the overall 
treatment into feasible fractions and implicitly enforce per-fraction limits. 
  
However, as the geometrical conditions change in adaptive planning, e.g. due to tumor 
shrinkage/growth (Kupelian et al., 2005; Siker et al., 2006; Ramsey et al., 2006; Underberg et 
al., 2006; Bosmans et al., 2006; Haasbek et al., 2007) or inter-fractional motion (Yan and 
Lockman, 2001; Yan et al., 2005), a normal tissue which would have satisfied its bound with 
slack in the initial plan is now pushed closer to its limit in the re-optimized plan. This creates a 
circumstance where the conditions for equal division of the adapted plan into fractions can no 
longer be satisfied easily.   
 
This chapter demonstrates the problem of fractionating the adaptive plans by using another lung 
case simulating real practice. The optimization model is formulated as a linear programming 
formulation which is a mathematical representation of the prescription. The plan is first 
optimized over the entire set of cumulative constraints and delivered for the first sub-sequence of 
fractions (Epoch 1). Here, epoch defines a subsequence of fractions delivered as part of the 
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adaptive plan. After subtracting the delivered doses from the cumulative limits, the treatment 
plans are re-optimized partway through treatment in response to the changes in the tumor 
geometry. The challenge of fractionating the re-optimized plan is demonstrated by computational 
experiments performed with varying mean dose limit on both lungs and implicit minimum tumor 
fraction size dose limits.  
 
3.2 Description of the Lung1 Test Case 
This section describes the second lung test case treated here, referred as “Lung1”, which is used 
in the computational experiments in Chapter 3 and 4. The points for optimization were 
distributed throughout the contours, determined randomly within each structure volume for 
computation efficiency rather than employing a uniform point set. They were more highly 
concentrated within the target and the critical structures of interest (Morrill et al., 1990; 
Niemierko and Goitein, 1990; Lu and Chin, 1993; Niemierko and Goitein, 1993; Acosta et al., 
2009). Number of sample points used (the mean distance to the nearest neighbor point) is 683 
(0.25 cm) for primary target PTV1, 95 (0.32 cm) for the esophagus, 400 (0.57 cm) for the heart, 
500 (0.73 cm) on each of the lungs, 369 (0.21 cm) for spinal cord, and 2,580 (0.65 cm) for the 
Not Otherwise Specified tissue. The influence matrix of aij was calculated by using the standard 
radiation therapy software GRATIS (Sherouse Systems Inc.). For this test case, 9 co-planar beam 
angles are used, spaced at intervals of 40° within the range of 20°-340°.  
 
Table 3.1 shows the prescription used in the computational experiments with the lung test case. 
The table presents both cumulative dose objectives and fraction size dose limits for the target and 
healthy tissues in the prescription. All of the points in each structure are subject to its 
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corresponding fraction size limit. Multiple values are shown for some structures varied in 
experiments to be reported below.  
 
Table 3.1: Prescription for the Lung1 Test Case 
       Note: PTV1 represents the planning target volume. 
 
3.3 Adaptive Planning Optimization 
The adaptive planning optimization approach taken in this study pursues the following steps. 
First, the LP-formulation presented in Section 2.3.1 is solved over all cumulative constraints. 
Then, an integer upper bound ( N ) and an integer lower bound ( N ) on the number of fractions 
(N) are computed. Upper limit N  is calculated as the maximum number of fractions into which 
the tumor dose can be divided without violating fraction size requirement dailytumorl , i.e.  dailytumormin l/D . 
Similarly, lower limit N  reflects the minimum number of fractions into which does for all 
healthy tissues k can be divided while enforcing fraction size maximum dailyku , i.e. 
 KKk,Hi:u/dmax kdailyki  . When there is a feasible outcome with NN   the treatment 
Structure Cumulative Dose  Objective (Gy) 
Fraction Size 
Dose Limit (Gy) 
Primary Target (PTV1) 
Maximize avg. dose 
≥ 1.8, 1.9, 2.0 
95.0
dosetumor max.
dose tumor min.   
Right Lung Mean dose ≤ 20, 22, 25 ≤ 2.1 
Left Lung Mean dose ≤ 20, 22, 25 ≤ 2.1 
Heart Mean dose  ≤ 35 ≤ 2.1 
Esophagus Mean dose  ≤ 35 ≤ 2.1 
Not Otherwise Specified Tissue 100%  ≤ 100 ≤ 2.1 
Spinal Cord 100%  ≤ 45 ≤ 2.1 
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plan is divided into N  fractions, and the first N1 are delivered in Epoch 1 before the patient is 
re-imaged.  
 
Following the first epoch, the PTV1 volume is updated based on the tumor shrinkage 
information extracted from simulated re-imaging. After revising the cumulative dose limits by 
subtracting the delivered doses, the treatment plan is re-optimized by solving the LP-formulation 
against the residual cumulative dose limits that maximizes the mean dose delivered to the 
residual tumor. Then, Epoch 2 fraction upper bound,  dailytumorremainingmin l/DN 2  fractions are 
delivered during the second epoch of the treatment where remainingminD  represents the minimum 
tumor dose achieved in the re-optimized plan.  
  
3.4 Results 
3.4.1 Computational Experiments – Overall Plan and Epoch 1 
To illustrate the fractionation problem in adaptive planning, complete plans without adaptation 
are first computed for a range of mean doses of the lungs and tumor fraction limits. Table 3.2 
shows that the optimized plan in the beginning of the treatment can be divided into integer 
number of feasible fractions (N) when ≥1.8 Gy tumor fraction size requirement applies. In this 
case, an integer N can be found within the range between lower and upper bound on N (31≤N≤32 
for mean dose limit 20 Gy, 34≤N≤35 for 22 Gy, 39≤N≤40 for 25 Gy). For varying mean dose 
limits of 20 Gy, 22 Gy and 25 Gy on lungs, the treatment plan is divided into 32, 35, and 40 
fractions, respectively, in which all the tumor points receive fraction size doses ≥1.8 Gy and all 
healthy tissue points receive fraction size doses ≤2.1 Gy. 
  
Table 3.2: Optimal Non-Adaptive Plan Results over the Entire Range of Cumulative Constraints 
Mean 
dose 
limit 
on 
both 
lungs 
(Gy) 
Optimal Plan Results (All the cumulative dose 
requirements in Table 3.1 are satisfied.)  
Upper and lower bound 
on integer number of 
fractions (N) 
 
 
 
 
N
 
Tumor fx size 
limit 
≥2.0 ≥1.9 ≥1.8
Min. 
Tumor 
(Gy) 
Max. 
Right 
Lung 
(Gy) 
Max. 
Left 
Lung 
(Gy) 
Max. 
Heart 
(Gy) 
Max. 
Esoph. 
(Gy) 
Max. 
N.O.S. 
(Gy) 
Max. 
Cord 
(Gy) 
N  N  N  
≤20 58.8 60.9 43.2 55.8 45.6 64.8 45.0 31 29 30 32 
≤22 64.4 67.2 46.9 61.3 49.4 71.4 45.0 34 32 33 35 
≤25 72.8 76.4 52.4 70.4 55.2 80.8 45.0 39 36 38 40 
Notation: N  is the integer lower bound on N dividing all the healthy tissues’ doses into fraction sizes  
of ≤2.1, N  is the integer upper bound on N dividing all the target doses by the assumed tumor fraction  
limit. “N.O.S.” is the abbreviation of “Not Otherwise Specified” tissue. Number of fractions to feasibly  
divide each plan is indicated in bold.  
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Following the adaptive planning approach of Section 3.3, the first 25 of those fractions are 
assumed to be delivered during the first epoch. Table 3.3 shows fraction size and the Epoch 1 
cumulative dose statistics that result for the structures under interest. Note that all fraction limits 
are satisfied. 
 
Table 3.3: Epoch 1 Optimal Plan Results 
Mean 
dose 
limit 
on 
both 
lungs 
(Gy)  
Epoch 1 (first 25 fractions) Optimal Plan Results (≥1.8 Gy tumor fraction size 
requirement applies.) 
Min. 
Tumor 
(Gy) 
Max. 
Tumor 
(Gy) 
Avg. 
Tumor 
(Gy) 
Max. 
Right 
Lung 
(Gy) 
Max. 
Left 
Lung 
(Gy) 
Max. 
Heart 
(Gy) 
Max. 
Esoph. 
(Gy) 
Max. 
N.O.S. 
(Gy) 
Max. 
Cord 
(Gy) 
≤20 45.8 [1.83] 
48.3 
[1.93] 
47.1 
[1.89] 
47.6 
[1.9] 
33.7 
[1.35]
43.6 
[1.74] 
35.6 
[1.43] 
50.5  
[2.02] 
35.2 
[1.41] 
≤22 46.0 [1.84] 
48.4 
[1.94] 
47.3 
[1.89] 
47.9 
[1.92]
33.6 
[1.34]
43.7 
[1.75] 
35.2 
[1.41] 
50.9  
[2.04] 
32.1 
[1.29] 
≤25 45.4 [1.82] 
47.8 
[1.91] 
46.7 
[1.87] 
47.8 
[1.91]
32.8 
[1.31]
44 
[1.76] 
34.5 
[1.38] 
50.5  
[2.02] 
28.1 
[1.13] 
Note: Fraction size doses are given in brackets below cumulative doses. “N.O.S.” is the 
abbreviation of “Not Otherwise Specified” tissue. 
  
3.4.2 Computational Experiments – Adaptation and Epoch 2 
For the purpose of experimentation, the tumor shrinkage is simulated where the residual tumor 
corresponds to the 65% of the original tumor after fraction 25 (See Section 4.4.1 for details). 
After delivering 25 fractions in Epoch 1, the treatment plan is re-optimized based on the updated 
image against residual cumulative dose limits.  
 
Table 3.4 shows the Epoch 2 dose statistics and fraction limits obtained from re-optimization. 
Only statistics related to Heart and Not Otherwise Specified tissues are shown here due to their 
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dominant role in determining the lower bound on the integer number of fractions that the re-
optimized treatment plan can be delivered into (denoted N2).   
 
Table 3.4: Epoch 2 Optimal Plan Results 
Mean 
dose 
limit 
on 
both 
lungs 
(Gy) 
Epoch 2 Optimal Plan Results (In response to the 
tumor geometrical changes, the treatment plan is 
re-optimized against the residual cumulative 
dose limits.) 
Upper and lower bound 
on the number of 
fractions in the re-
optimized plan (N2) 
 
 
 
2N
 
Tumor fx size limit
≥2.0 ≥1.9 ≥1.8
Min. 
Tumor 
(Gy) 
Max. 
Tumor 
(Gy) 
Mean 
Tumor 
(Gy) 
Max. 
Heart 
(Gy) 
Max. 
Not 
Otherwise 
(Gy) 
2N  2N  2N  
≤20 14.7  20.3 17.5 18.5 20.9 10 7 7 8 
≤22 21.6 27.7 24.6 24.7 28.7 14 10 11 11 
≤25 32.3  38.9 35.6 32.8  41.9  20 16 17 17 
 
The cases show that the adapted plan in Epoch 2 using only cumulative constraints can only be 
divided into fractions satisfying tumor fraction size requirements at the price of violating the 
fraction size dose limits of some healthy tissue structures. Similarly, the adapted plan can be 
divided into fractions where all healthy tissue fraction size dose limits are satisfied without the 
tumor fraction size limit being satisfied. No number of fractions meets all requirements. 
 
These violations are displayed in Figure 3.1(a-c) for different mean dose limits on each lung. For 
example, for mean dose limit 20 Gy, the adapted plan can be divided into 7 fractions satisfying 
≥2 Gy tumor fraction size requirement while violating the ≤2.1 Gy requirement on Heart and Not 
Otherwise Specified tissue (2.64 Gy ≥ 2.1 Gy for Heart, 2.99 Gy ≥ 2.1 Gy for Not Otherwise 
Specified tissue). These plots illustrate that as the tumor fraction size requirement is relaxed from 
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≥2 Gy to ≥1.8 Gy, the ≤2.1 Gy requirement on Heart and Not Otherwise Specified tissues are 
less violated, but not fully satisfied. 
 
Figure 3.1(a-c) also presents the number of fractions into which the adapted treatment plan can 
be divided in order to satisfy all the healthy tissue fraction size requirements. However, this 
causes tumor to be significantly underdosed (1.47 Gy minimum dose for mean dose limit 20 Gy, 
1.54 Gy minimum dose for 22 Gy, and 1.62 Gy minimum dose for 25 Gy).  
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Figure 3.1: Sensitivity of Healthy Tissue and Target Fraction Size (fx) Doses in Epoch 2 (a) For 
Mean Dose Limit on Both Lungs 20 Gy (b) For Mean Dose Limit on Both Lungs 22 Gy (c) For 
Mean Dose Limit on Both Lungs 25 Gy (“NOS” is the abbreviation of “Not Otherwise 
Specified” tissue.) 
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3.4.3 Computational Experiments – Potential Gains with Adaptation 
Although the above treatment plans generated by adaptation are not feasible due to the lack of 
fractionation in the second epoch, they are compared against plans generated by no adaptation in 
Table 3.2 to assess the gains that could be realized from adaptive planning. Figure 3.2 
summarizes the mean tumor doses delivered to the tumor by no adaptation (Table 3.2) versus 
two-epoch adaptation (Epoch 1 in Table 3.3 and Epoch 2 in Table 3.4) for varying mean dose 
limits on the lungs. Here, ≥1.8 Gy tumor fraction size requirement is enforced in delivering 
Epoch 1. Adapting the treatment plan boosts the mean tumor dose from 60.3 Gy to 64.7 Gy for 
mean dose limit 20 Gy, from 66.2 Gy to 71.9 Gy for 22 Gy, and from 74.6 Gy to 82.2 Gy for 25 
Gy. These improvements correspond to a 7% to 10% gain in the doses delivered to the tumor. 
 
Figure 3.2: Average Tumor Doses Received by No Adaptation vs. Two-Epoch Adaptation 
 
3.5 Discussions 
Chapter 3 addresses the problem of fractionation in the adaptive planning context. As a 
consequence of solely taking cumulative dose objectives into account in the treatment planning 
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optimization, plans re-optimized in response to the changes in the geometrical conditions can 
provide dose distributions that do not allow the adapted plan to be divided into fractions 
satisfying both the minimum fraction size requirement placed on tumor (e.g. ≥1.8 Gy) and the 
maximum fraction size requirement placed on healthy tissues (≤2.1 Gy). In this case, the 
practitioners must take the approach of relaxing the fraction size dose requirements in order to 
achieve a least violated fractionation plan which would likely reduce the efficacy of the overall 
treatment plan.  
 
Specifically, the fractionation challenge is illustrated above by using a lung test case simulating 
real practice. Treatment plans are re-optimized partway through treatment by incorporating the 
latest tumor shrinkage information. With the re-optimization in the experiments, structures Heart 
and Not Otherwise Specified receive more dose relative to the tumor which does not allow 
feasible fractionation of the adapted plan. The minimum number of fractions required for healthy 
tissue doses to be given in fraction sizes below 2.1 Gy is significantly higher than the maximum 
number of fractions that the tumor dose distribution can be given without falling below about 1.8 
Gy (Table 3.4). When the adapted plans are divided, the violations of healthy tissue fraction sizes 
doses can be as significant as 3 Gy per fraction whereas the tumor fraction size doses can fall 
down to 1.47 Gy (Figure 3.1(a-c)). 
 
The fractionation challenge investigated in this study motivates devising methodologies that 
simultaneously re-optimize treatment plans against both cumulative and fraction size dose limits 
in adaptive plans with two or more epochs. Although the gain obtained from adaptation (Figure 
3.2) might reduce as the fraction size limits are explicitly enforced in the re-optimization, 
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simultaneous methods would allow the feasible division of the adapted plans; therefore, 
increasing the effectiveness of the treatment delivered.      
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4 Adaptive IMRT Planning Optimization with Changing Tumor Geometry and Fraction 
Size Limits 
Adaptive planning responds to the changes in the tumor geometry throughout the treatment and 
demands both cumulative and fraction size limits on tissues be satisfied together. The changes in 
the tumor geometry between fractions known as inter-fractional changes happen mostly in two 
forms: (1) the change in the position/shape of the tumor due to inter-fraction motion, e.g. 
positional change of the prostate tumor due to how much the bladder/rectum is filled on the 
particular day (Yan and Lockman, 2001; Yan et al., 2005), (2) the change in the tumor size, e.g. 
tumor shrinkage/growth in lung cases (Kupelian et al., 2005; Siker et al., 2006; Ramsey et al., 
2006; Underberg et al., 2006; Bosmans et al., 2006; Haasbek et al., 2007). These inter-fractional 
changes can be captured by the updated images acquired through the treatment and incorporated 
into the planning to update the remaining plan accordingly. 
 
In this study, the change in the tumor size/shape, specifically tumor shrinkage information over 
time, is taken into account to adapt the treatment plan. This chapter develops a promising 
adaptive planning optimization methodology which re-optimizes the treatment plan against both 
cumulative and fraction size dose constraints after delivering each epoch by incorporating the 
latest tumor shrinkage information. In re-optimizing the treatment plan at each adaptation point, 
a mixed-integer linear programming (MILP) formulation is solved; therefore, a series of MILPs 
will be solved in the proposed methodology to adapt the plan periodically. 
 
The adaptive treatment plans computed by the developed optimization methodology are 
compared with the treatment plans generated without adaptation (non-adaptive) by using the two 
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realistic Lung test cases described in Section 2.1 (“CERRLung”) and Section 3.2 (“Lung1”). The 
prescription in Table 1.1 is used for CERRLung case whereas the prescription in Table 3.1 is 
used for Lung1 case. Note that the secondary target PTV2 is included in the Lung1 case with the 
same prescription in Table 1.1, and ≥2Gy fraction size requirement for tumor and mean dose 
limit of 25 Gy is used for both lungs. The non-adaptive plans in this chapter are generated by 
solving the uniform fractionation model presented in Section 2.5 or a non-adaptive planning 
optimization with boost approach explained in Section 4.4.2. The computed adaptive plans both 
satisfy cumulative and fraction size dose limits while improving the tumor doses.  
 
4.1 Literature Review 
The available methods used to generate radiation therapy plans optimize a single cumulative 
treatment plan and neglect changes in the tumor over time. Besides these non-adaptive methods, 
several approaches for adaptive treatment planning have been developed by operations 
researchers. In most of these approaches, the uncertainty in the tumor geometry caused by 
internal organ movements and set up-errors (random changes in the patient position) across all 
fractions are incorporated into the treatment planning. In order to generate IMRT plans under 
this uncertainty, a dynamic programming approach with practical strategies (Ferris and Voelker, 
2004; Deng and Ferris, 2006), weighted power loss function approach calculating the ideal 
spatial dose distribution (Sir et al., 2006), and a probabilistic model achieving robust 
optimization (Chu et al., 2005) have been presented. 
 
Recently, in the medical world, the reimaging of gross tumor boundaries over time has been 
introduced into the clinic. Devices now widely available allow periodic CTs to be performed on 
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the treatment couch (using cone beam or rail methods) and cross registered using fiducial 
markers against the planning CT (Wiersma et al., 2007). The first image guided therapies in 
radiation accommodated rigid change in geometry by moving the treatment couch in space, a 
technique now widely implemented to "adapt" to a rigid shift of the body or target over time (Wu 
et al., 2006). More sophisticated re-optimizations over the course of treatment based on observed 
change in shape have now been examined. Many set a goal of minimizing the difference between 
the initially intended and the final achieved dose distributions; linear programming proved 
desirable for its speed and promise of optimality (Wu et al., 2008). A broader extension 
considers re-optimizations on the underlying tissue constraints rather than simply matching to the 
original plan when structure outlines are found to have changed (Wu et al., 2002). The advent of 
a commercial system (“Planned Adaptive” marketed by Tomotherapy of Madison, WI) that 
captures physical change over the course of treatment replans using cumulative doses, and is 
linked to a reproducible system for delivery that has established the concept of adaptive radiation 
therapy in the minds of oncologists as a tool by which gains in tumor control can be achieved 
(Woodford et al., 2007).  
 
None of these adaptive approaches have succeeded in optimizing against both cumulative dose 
limits and dose limits placed on each fraction. This deficit may have slowed their adoption into 
regular practice, but increased use is expected as the technology becomes increasingly familiar, 
pitfalls are identified, and workarounds are devised to satisfy fraction size rules even at the price 
of diminishing the potential gains from the adaptive strategy. This chapter aims to help meet this 
deficit by developing an adaptive planning approach that re-optimizes the treatment plan against 
both cumulative dose limits and dose limits placed on each fraction simultaneously when it can 
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be productive to do so. A paper on the proposed adaptive planning approach has recently been 
accepted for publication (Saka et al., 2011).   
 
4.2 Uniform and Non-Uniform Fractionation Model and Rationale 
The uniform fractionation model described in Section 2.5 produces a single uniform plan across 
all fractions. One could propose improving the average tumor dose received from uniform 
fractionation by splitting the treatment plan into two stages where different plans would be used 
for each stage. Stage defines a subsequence of fractions delivered as part of a non-adaptive plan. 
That is, no changes in geometry are taken into account. 
 
4.2.1 Non-Uniform Fractionation Model with Two-Stage Optimization 
The non-uniform fractionation model is developed to optimize the treatment plan over two stages 
where new beamlet intensities for each stage are defined. Let 1jx  and 
2
jx  be intensities assigned 
to beamlet Jj  during stage 1 and 2, respectively. The total dose delivered to point i during the 
first stage is denoted as 1id  and equal to 
Jj
jij xa
1 . Similarly, 2id  denotes the total dose delivered 
to point i during the second stage and equal to 
Jj
jij xa
2 . 
 
Table 4.1 presents this non-uniform fractionation model for two-stage optimization. It maximizes 
the average dose delivered to the tumor over two stages. Constraint sets (4.1) through (4.5) are 
the overall treatment constraints imposed over two stages and have the same nature as the 
constraint sets (2.3) through (2.7) presented previously in Section 2.3.1. Constraint sets (4.6) 
through (4.8) impose lower dose limits on the secondary target and tumor points, and the upper 
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dose limits on all healthy tissue points for the N1 fractions in the first stage. These integer 
fractionation constraints guarantee that the treatment plan in Stage 1 is delivered in uniform, 
feasible fractions. Here, N1 is a choice for the number of equal fractions employed in the first 
stage. For instance, if the treatment plan is split after fraction 10, then N1 is equal to 10.  
 
For the plan delivered in the second stage, an integer variable N2 defines the number of fractions 
given during the second stage. Constraint sets (4.9) through (4.11) impose lower dose limits on 
the secondary target and tumor points, and the upper dose limits on all healthy tissue points for 
the N2 fractions in the first stage. These constraints guarantee that the plan delivered in second 
stage can be divided in N2 uniform, feasible fractions. 
 
Table 4.1: Non-Uniform Fractionation Model for Two-Stage Optimization 
Objective and the Overall Treatment Constraints 
T/dd
Ti
ii 

 

21maximize  
kk
Hi
ii Hdd
k


21
 
Kk                (4.1)
total
kii udd  21  kHi,Kk                (4.2)
total
secii ldd  21  Si                       (4.3)

min
ii
Ddd  21  Si                                                  (4.4)  

min
iimin
DddD  21
 
Ti                (4.5)
Integer Fractionation Constraints for 
 Stage 1 
Integer Fractionation Constraints for Stage 
2 
1
1 Nld dailyseci   Si                   (4.6)
1
1 Nld dailytumori   Ti                   (4.7)
1
1 Nud dailyki   kHi,KKk  (4.8)
2
2 Nld dailyseci   Si                      (4.9)
2
2 Nld dailytumori   Ti                    (4.10)
2
2 Nud dailyki  kHi,KKk  (4.11)  
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4.2.2 Rationale for Non-Uniform Fractionation in Adaptive Planning 
Unless the treatment environment such as the patient geometry, the selected beam angles or the 
optimization parameters changes, this research found that it does not help to split the course of 
the treatment and deliver non-uniform fraction plans. This finding is proven by the following 
lemmas and stated as a theorem at the end.   
 
Let x1 and x2 vectors of |J| size where their components correspond to variables 1jx  and 
2
jx  for 
Jj , respectively. Let x be a vector of |J| size where its components correspond to variables xj 
for Jj .  
 
Lemma 1: Any feasible solution  221 N,x,x  for non-uniform fractionation model can be mapped 
to a feasible solution  N,x  for uniform fractionation model by using 21 xxx   and 
21 NNN  , and their objective function values are same. 
Proof: Since   221 N,x,x  is a feasible solution for non-uniform fractionation model, it satisfies 
the overall treatment constraint sets (4.1) through (4.5). Then, re-writing 21 ii dd   in those 
constraint sets by using expression (4.12), 21 xxx   satisfies them, and they are same as the 
overall treatment constraint sets (2.3) through (2.7) of the uniform fractionation model in Section 
2.5. Therefore,  N,x  satisfies the overall treatment constraints in uniform fractionation model. 
   i
Jj
jij
Jj
jjij
Jj
jijjij
Jj
jij
Jj
jijii dxaxxaxaxaxaxadd  

21212121    (4.12) 
As part of the feasibility,  221 N,x,x  also satisfies the integer fractionation constraints for each 
stage. Adding integer fractionation constraint sets across two stages for each tissue and using the 
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same expression (4.12) to re-write those three added inequalities, 
2
1 xxx   satisfies them 
where 21 NNN  . These inequalities are the same as the fractionation constraint sets (2.16) 
through (2.18) in uniform fractionation model in Section 2.5. Therefore,  N,x  satisfies the 
fractionation constraints in uniform fractionation model. 
 
Since  N,x  satisfies both overall treatment and integer fractionation constraints in uniform 
fractionation model, it is a feasible solution. Its objective function is equal to the objective 
function of  221 N,x,x , because re-writing  the objective function of   221 N,x,x  which is 
|T|/dd
Ti
ii 

 

21  by using expression (4.12) , the objective function of  N,x  which is
|T|/d
Ti
i 



 is obtained. É 
 
Lemma 2: Any feasible solution  N,x  for uniform fractionation model can be mapped to a 
feasible solution  221 N,x,x  for non-uniform fractionation model by using 
x
N
Nx,x
N
Nx 2211   and 12 NNN  , and their objective function values are same. 
Proof: Since  N,x  is feasible for uniform fractionation model, it satisfies the cumulative dose 
constraint sets (2.3) through (2.7) and integer fraction size dose constraint sets (2.16) through 
(2.18). When those constraints are re-written by using expression (4.13), x
N
Nx 11   and 
x
N
Nx 22   where 12 NNN   satisfy those constraints which are identical to the constraints in 
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non-uniform fractionation model. Therefore,  221 N,x,x  is a feasible solution for the non-
uniform fractionation model.   
 21212111 ii
Jj
jij
Jj
jij
Jj
jij
Jj
jij
Jj
jjij
Jj
jiji ddxaxaxN
Nax
N
Nax
N
NNx
N
Naxad 





  
      
(4.13) 
The objective function of  221 N,x,x  is equal to the objective function of  N,x , because by re-
writing |T|/d
Ti
i 


  
using expression (4.13), the objective function |T|/dd
Ti
ii 

 

21  is 
received. É 
 
Theorem: The optimal solution values for uniform and non-uniform models are equivalent in 
the sense that the optimal solution to either model can be converted to a feasible solution of other 
with the same objective function value.  
Proof: Without loss of generality, pick up the optimal solution for non-uniform fractionation 
model. By using Lemma 1, this optimal solution can be mapped to a feasible solution for 
uniform fractionation model with the same objective function value. Suppose there is a better 
solution for uniform fractionation model than this feasible solution. Then, by Lemma 2, it could 
be mapped back to a feasible solution with the same objective function value for non-uniform 
fractionation model which would have a higher objective function value than the optimal 
solution which creates a contradiction. Therefore, by contradiction, the feasible solution for 
uniform fractionation model mapped from the optimal solution for non-uniform fractionation 
model is optimal for the uniform fractionation model. É  
  
Note that by induction any use of non-uniform plans across multiple stages over the course of the 
treatment would not help the tumor doses received from delivering uniform plan across all 
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fractions unless something in the treatment environment changes such as the patient geometry, 
the selected beam angles or the optimization parameters changes. However, there is a potential 
value for re-optimizing the treatment plan over time and producing time-varying plans when the 
treatment environment changes. This justifies the idea of adapting treatment plans over the 
course of the treatment when the changes in the tumor geometry are observed.    
 
4.3 Adaptive Planning Optimization Methodology 
It is assumed that the beamlets of beam angles are pre-selected prior to the optimization. In the 
proposed approach, only a cumulative dose homogeneity requirement for tumor is considered. 
Epoch-based re-imaging is assumed, so the treatment plan is adapted after delivering each epoch. 
As previously stated, a mean dose limit is used for healthy tissues with dose-volume limits. 
Lastly, only the tumor is subject to geometrical change over the course of the treatment.  
 
For the methodology, a few new notations are defined. Let T denote the set of residual tumor 
points having radiological evident disease through the treatment, and D denote the set of 
removed tumor points locating in tumor volume not currently radio graphically apparent as 
disease, but which was formerly occupied by tumor. The points in the set D are subject to the 
secondary target prescription.   
 
4.3.1 Optimization Methodology 
The process for the methodology is given below. The counter for the iterations is denoted as m. 
Let M denote the number of adaptation points throughout the treatment, so the treatment plan is 
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periodically adapted M times which indicates that there are M+1 epochs. deliveredid  denotes dose 
delivered at each tissue point and initially equal to 0 for all points. 
 
For m = 0 to M 
 Acquire new image. 
Update residual tumor volume by removing tumor points from the set T into the set D. 
Revise the cumulative dose limits for the remaining plan according to the delivered plans. 
Solve the re-optimization formulation to determine the immediate plan. 
 Deliver the fractions in the immediate plan. Update deliveredid  for each tissue point. 
Next m 
 
The methodology iterates M+1 times. The first iteration (m=0) occurs at the beginning of the 
treatment plan where no shrinkage is observed; therefore, the set T includes all the points in the 
original tumor while the set D is empty. In the rest of the iterations, tumor shrinkage is reflected 
by removing tumor points into the set D. In the methodology, each time the immediate plan is 
delivered, the time horizon is rolled forward by an epoch.  
 
4.3.2 Re-optimization Formulation 
At each adaptation point, the treatment plan is re-optimized by solving the formulation given in 
Figure 4.1. For the illustration purpose, this figure assumes that epochs 1…m has been delivered 
and the immediate plan for epoch m+1 will be determined. The re-optimization formulation 
optimizes the remaining plan against residual cumulative dose limit constraints and remaining 
plan fractionation constraints, and then the first N1 optimal fractions are delivered for the 
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immediate plan which is labeled as a dashed rectangle in Figure 4.1. Here, N1, a clinician defined 
parameter, represents the duration of the immediate plan. For example, if patient is re-imaged 
and the plan is updated bi-weekly, N1=10. 
 
Optimizing the remaining plan requires defining one set of continuous variables for the 
intensities of the beamlets in the remaining plan. Let xj be the continuous variable defined for the 
intensity of beamlet Jj  in the remaining plan. Then, dose delivered to point i in the remaining 
plan denoted as di is computed as 
Jj
jij xa .  
 
Figure 4.1: Re-optimization Formulation 
 
The formulation in Figure 4.1 maximizes the average tumor dose delivered to residual tumor 
points Ti  in the remaining plan subject to overall treatment and remaining plan fractionation 
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constraints. Constraint sets (4.14) through (4.18) make sure that cumulative dose limits for dose-
volume healthy tissues, healthy tissues, secondary target and removed tumor points, and residual 
tumor points are maintained, respectively.  
 
Constraint sets (4.19) through (4.21) impose lower dose limits on the secondary target, removed 
tumor and residual tumor points, and upper dose limits on healthy and dose-volume healthy 
tissue points for the N fractions in the remaining plan. Here, N is an integer variable and defined 
as the number of fractions in the remaining plan. These constraints on remaining plan ensure that 
the remaining plan can be delivered in N equal, feasible fractions.  
 
At each iteration, except the last one, N1 of these N optimal fractions are delivered in immediate 
plan, and the methodology moves to the next iteration. However, at the last iteration where the 
final adaptation occurs, all the N optimal fractions in the remaining plan are delivered in the last 
epoch.  
 
In the re-optimization formulation, the immediate plan and the prospective plan (the remaining 
timeline after N1 fractions) are combined into a remaining plan. It would be desired to treat them 
separately if the new conditions in the prospective plan were considered, e.g. further tumor 
shrinkage.  However, this research considers the simplest case where the tumor geometry in the 
immediate and prospective plan is the same. It would not help the optimization results to treat 
them separately as a consequence of the finding stated previously. Moreover, treating them 
separately in this simplest case would require defining two sets of variables and two sets of 
fractionation constraints which would worsen the computational efficiency of the formulation.  
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Note that a simple relaxation of the integer variable N into a continuous variable may lead to 
infeasibility when the optimal fractional value of N is further rounded up or down as illustrated 
in Table 4.2. This motivates defining N as an integer variable in the re-optimization formulation. 
 
Table 4.2: Infeasible Fractionation from Solving the LP-relaxation of the Re-optimization 
Formulation at the First Iteration for the Lung1 Case (Violations of fraction size requirements are 
in bold and highlighted.) 
Structure Dose Statistics 
Cum. 
dose 
(Gy) 
Fract. size 
dose (Gy) 
when N=34.7 
is rounded 
down to 34 
Fract. size 
dose (Gy) 
when N=34.7 
is rounded up 
to 35 
Tumor Min. dose 71.3 2.10 2.04 
PTV2 Min. dose 69.4 2.04 1.98 
Right Lung Max. dose 72.8 2.14 2.08 
Left Lung Max. dose 56.1 1.65 1.60 
Heart Max. dose 70.9 2.08 2.02 
Esophagus Max. dose 59.5 1.75 1.70 
Not Otherwise 
Specified Max. dose 72.8 2.14 2.08 
Spinal Cord Max. dose 45.0 1.32 1.29 
Notation: N is the number of fractions the treatment plan is divided into and equal  
to 34.7 in the relaxation. 
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with some percentage, such as 10%, 30% and 50%, for the experiments where the treatment plan 
is adapted during the subsequent fractions after fraction 25.  
 
4.4.2 Two-Epoch Adaptation Results 
For two-epoch adaptation experiments, the treatment plans for both test cases are adapted once 
after fraction 25 based on the generated residual tumor volumes and compared with treatment 
plans generated with no adaptation (non-adaptive). When the treatment plan is adapted after 
fraction 25, the minimum fraction size limit constraints on the secondary target PTV2 and the 
removed tumor points (part of the original tumor during the first 25 fractions) are dropped from 
the re-optimization formulation since these points satisfy their prescribed cumulative dose limits 
(≥50 Gy) by receiving fraction size doses at least or greater than their required minimum limits 
during the first 25 fractions and there is no clinical need to deliver the minimum fraction size 
doses to these points during the subsequent fractions. Thus, dropping these constraints relaxes 
the re-optimization formulation and creates freedom.  
 
Non-adaptive plans are first prepared by non-adaptive planning optimization without boost 
employed in most of the commercial products. In order to have a fuller comparison between non-
adaptive and adaptive plans, a non-adaptive planning optimization with boost was also employed 
where the treatment plan is re-optimized after fraction 25 by dropping the fraction size limit 
constraints on PTV2 points without acquiring an updated image (For non-adaptive plans, “main 
stage” includes the first 25 fractions and “boost stage” includes fractions after re-optimization).  
The non-adaptive planning optimization with boost is motivated by the clinical desire to design 
treatments with a boosting strategy (employed in commercial systems) which uses different 
 uniform f
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Non-adaptive optimization without boost delivers minimum dose of 2 Gy/fraction to PTV2 
points over the course of the treatment. By non-adaptive optimization with boost, the PTV2 
points receive minimum dose of 0.9 Gy/fraction for Lung1 Case and minimum dose of 0.91 
Gy/fraction for CERRLung case during the boost stage since the fraction size limit (≥2 Gy) on 
PTV2 points are not imposed in the re-optimization after fraction 25. This freedom created in 
non-adaptive optimization with boost improves the average tumor dose achieved in the boost 
epoch by 0.5 Gy for Lung1 case, so the average cumulative dose achieved by non-adaptive 
optimization without boost increased from 72.9 Gy to 73.4 Gy. The effect of the freedom on the 
optimization results is more significant in CERRLung case. Re-optimizing the treatment plan 
better spares the right lung by delivering average dose of 0.35 Gy/fraction after fraction 25 
compared to the average dose of 0.47 Gy/fraction by non-adaptive optimization without boost. 
The reduction in the average dose that right lung receives allows adding 4 more fractions to the 
boost epoch and boosts the cumulative dose from 76.2 Gy to 84.9 Gy.   
 
When the treatment is adapted to the tumor shrinkage after fraction 25, the right lung is better 
spared during the second epoch by receiving average dose of 0.6 Gy/fraction in Lung1 case and 
0.31 Gy/fraction in CERRLung case compared to the 0.71 Gy/fraction and 0.35 Gy/fraction 
received from non-adaptive optimization with boost for both test cases, respectively. Better 
sparing the right lung is achieved by taking advantage of the extra freedom created in the re-
optimization formulation by dropping the minimum fraction size limit constraints on the 
removed tumor points. The removed tumor points receive minimum dose of 0.53 Gy/fraction 
during the second epoch (with boost) for Lung1 case and minimum dose of 0.65 Gy/fraction for 
CERRLung case. However, same points are required to receive 2 Gy/fraction in non-adaptive 
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plans. The reduction in the average dose/fraction that the right lung receives during the second 
epoch allows increasing the number of fractions delivered in the second epoch from 10 to 12 for 
Lung1 case and from 15 to 17 for CERRLung case.  
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Table 4.3: No Adaptation and Two-Epoch Adaptation Results for Lung1 and CERRLung Test 
Cases (The uniform fractionation model is solved in optimization, bold and highlighting signifies 
numbers referenced in the text.) 
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The overall tumor dose statistics received from no adaptation and two-epoch adaptation for 
Lung1 case are summarized in Figure 4.3(a). Adapting the treatment plan improves the overall 
tumor doses significantly. It adds 2 more fractions to the overall treatment and increases the 
average tumor dose by 5.3 to 5.8 Gy. This corresponds to over 7% boost in the average tumor 
dose. Figure 4.3(b) illustrates the improvement in the overall tumor doses achieved by adaptation 
for CERRLung case. Compared to non-adaptive optimization without boost, 6 more fractions are 
delivered in the treatment plan and average dose of 12.7 Gy (17%) gain is achieved by adapting 
the treatment plan once. Although re-optimizing the non-adaptive plan after fraction 25 improves 
non-adaptive planning results significantly, two-epoch adaptation still performs superior to no 
adaptation. In this case, the average tumor dose is boosted from 84.9 Gy to 88.9 Gy 
corresponding to a 4 Gy (4.7%) increase and 2 more fractions are delivered in the treatment plan. 
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       (a) Lung1 Case               (b) CERRLung Case 
Figure 4.3: Comparison of Overall Tumor Dose Statistics Received by No Adaptation and Two-
Epoch Adaptation (Number of fractions delivered in the overall treatment given in the 
parenthesis, the lower and upper bar on each column showing the minimum and maximum 
cumulative tumor dose achieved, respectively.) 
 
Increasing the delivered number of fractions by re-optimization in the non-adaptive plan with 
boost and adaptive plans may create very high hot-spots within the tumor. However, a 
homogeneity dose constraint is enforced in the re-optimization (constraint set (4.18) in Figure 
4.1) which should prevent having very low cold-spots as well as very high hot-spots at the end of 
the treatment. For example, as Table 4.3 shows, two-epoch adaptation plan for CERRLung case 
delivers minimum and maximum tumor doses of 86.4 Gy and 91.0 Gy, respectively,  which 
satisfies the prescribed tumor homogeneity dose limit (86.4/91.0≥0.95). As a result, enforcing 
tumor homogeneity dose constraint in the re-optimization imposes homogeneous tumor dose 
distribution to be delivered over the course of the treatment. Furthermore, an upper dose limit 
constraint on the removed tumor points is enforced in the re-optimization which would prevent 
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having very high hot-spots among the removed tumor points by ensuring that their cumulative 
doses do not exceed the maximum cumulative dose achieved in the tumor. 
 
It could be desired to bound the increase in the number of fractions by re-optimization due to 
clinical reasons, e.g. considering adjuvant therapies, such as chemotherapy. This could be easily 
done in the developed methodology by adding the following constraint N+Ndelivered≤U to the re-
optimization formulation given in Figure 4.1 where Ndelivered defines the number of fractions 
given in the delivered plan, and U is the clinician-defined parameter for the upper bound on the 
number of fractions delivered in the overall treatment. Nevertheless, adding this constraint might 
reduce the gains in average tumor dose achieved by adaptation.         
 
The detailed results for the computed plans on CERRLung test case given in Table 4.3 are shown 
in Table 4.4. Table 4.4 presents cumulative and fraction size dose statistics for each structure 
over each stage/epoch and the overall treatment as well as the number of fractions delivered in 
each time period in non-adaptive plans without or with boost and two-epoch adaptive plan. The 
dose statistics in Table 4.4 indicate that both cumulative and fraction size dose limits placed on 
each healthy tissue are satisfied in the non-adaptive and adaptive plans. For example, the right 
lung receives a mean dose of 17.0 Gy (≤17 Gy) in mean fraction size doses of 0.47 during 36 
fractions in the non-adaptive plan without boost. During each of these fractions, the maximum 
dose that the right lung receives is 2.1 Gy which is in accordance with its maximum fraction size 
limit (≤2.1 Gy). Furthermore, the other healthy tissues satisfy their cumulative dose limits being 
that the mean dose that the left lung receives is 9.7 Gy (<17 Gy), the heart receives 4.2 Gy (<35 
Gy), and the esophagus receives 16.8 Gy (<35 Gy). The maximum dose the not otherwise 
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specified tissue receives is 75.6 Gy (<100 Gy) and the spinal cord receives is 9.5 Gy (<45 Gy). 
These healthy tissues under interest receive fraction size doses less than or equal to their 
maximum fraction size limit during each fraction. Satisfaction of both the cumulative and the 
fraction size limits for each tissue carries over to the non-adaptive plan with boost and adaptive 
plans as Table 4.4 demonstrates. 
 
Since the developed re-optimization approach is to maximize dose delivered to the tumor within 
cumulative and fraction size tolerance levels of healthy tissues, rather than meeting a specific 
prescription for the tumor, some healthy tissues are dosed to its cumulative limit (e.g. Right lung 
receives average cumulative dose of 17 Gy in CERRLung case). However, this approach is in 
accordance with clinical studies on dose escalation (c.f. van Baardwijk et al., 2008; van 
Baardwijk et al., 2010) and the prescribed cumulative dose limits on healthy tissues are respected 
in the computed adaptive plans.  
 
The detailed dose statistics for Lung1 case are given in Appendix A. The results show that all 
cumulative dose limits for the overall treatment and fraction size dose limits for each stage/epoch 
fraction are satisfied in both non-adaptive and adaptive plans. 
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Table 4.4: No Adaptation vs. Two-Epoch Adaptation Results for the CERRLung Test Case (The 
uniform fractionation model is solved in the optimization.) 
Structure 
Dose 
Statistics 
(Gy) 
No 
Adaptation 
(No Boost)
No Adaptation (with 
Boost) Two-Epoch Adaptation 
Total Main Stage
Boost 
Stage Total 
Epoch
1
Epoch 2 
(with Boost) Total 
Tumor 
Max. 
Dose 
78.2 
[2.17] 
54.3 
[2.17]
34.9 
[2.33] 86.9 
54.3 
[2.17]
39.0 
[2.30] 91.0 
Min. 
Dose 
74.3 
[2.06] 
51.6 
[2.06]
30.0
[2.00] 82.5 
51.6 
[2.06]
34.0 
[2.00] 86.4 
Mean 
Dose 
76.2 
[2.12] 
52.9 
[2.12]
31.9 
[2.13] 84.9 
52.9 
[2.12]
36.0 
[2.12] 88.9 
Removed 
Tumor 
Points 
Max. 
Dose - - - - - 
37.7 
[2.22] 91.0 
Min. 
Dose - - - - - 
11.1 
[0.65] 64.5 
Mean 
Dose - - - - - 
32.0 
[1.88] 84.9 
PTV2 
Max. 
Dose 
78.2 
[2.17] 
54.3 
[2.17]
35.9 
[2.39] 86.9 
54.3 
[2.17]
40.0 
[2.35] 91.0 
Min. 
Dose 
72.0 
[2.00] 
50 
[2.00]
13.7 
[0.91] 63.7 
50 
[2.00]
4.2 
[0.25] 54.2 
Mean 
Dose 
75.3 
[2.09] 
52.3 
[2.09]
29.4 
[1.96] 81.6 
52.3 
[2.09]
30.9 
[1.81] 83.1 
Right Lung 
Max. 
Dose 
75.6 
[2.10] 
52.5 
[2.10]
31.5 
[2.10] 84.0 
52.5 
[2.10]
35.7 
[2.10] 88.2 
Mean 
Dose 
17.0 
[0.47] 
11.8 
[0.47]
5.2 
[0.35] 17.0 
11.8 
[0.47]
5.2 
[0.31] 17.0 
Left Lung 
Max. 
Dose 
75.6 
[2.10] 
52.5 
[2.10]
31.5 
[2.10] 82.0 
52.5 
[2.10]
32.3 
[1.90] 81.7 
Mean 
Dose 
9.7 
[0.27] 
6.7 
[0.27]
2.8 
[0.19] 9.6 
6.7 
[0.27]
2.6 
[0.16] 9.4 
Heart 
Max. 
Dose 
72.3 
[2.01] 
50.2 
[2.01]
25.4 
[1.69] 75.6 
50.2 
[2.01]
20.6 
[1.21] 69.7 
Mean 
Dose 
4.2 
[0.12] 
2.9 
[0.12]
1.0
[0.06] 3.9 
2.9 
[0.12]
1.0 
[0.06] 4.0 
Esophagus 
Max. 
Dose 
75.6 
[2.10] 
52.5 
[2.10]
24.8 
[1.65] 77.3 
52.5 
[2.1]
22.0 
[1.29] 74.5 
Mean 
Dose 
16.8 
[0.47] 
11.7 
[0.47]
3.5 
[0.23] 15.2 
11.7 
[0.47]
3.0 
[0.18] 14.7 
Not 
Otherwise 
Specified 
Max. 
Dose 
75.6 
[2.10] 
52.5 
[2.10]
31.5 
[2.10] 84.0 
52.5 
[2.10]
35.7 
[2.10] 88.2 
Mean 
Dose 
7.5 
[0.21] 
5.2 
[0.21]
2.4 
[0.16] 7.6 
5.2 
[0.21]
2.4 
[0.14] 7.6 
Spinal 
Cord 
Max. 
Dose 
9.5 
[0.26] 
6.6 
[0.26]
4.5 
[0.30] 10.6 
6.6 
[0.26]
7.2 
[0.42] 12.0 
Mean 
Dose 
1.7 
[0.05] 
1.2 
[0.05]
0.7 
[0.05] 1.9 
1.2 
[0.05]
0.5 
[0.03] 1.7 
# of Fractions Given 36 25 15 40 25 17 42
Note: The fraction size doses are given in brackets below the cumulative doses. PTV2 represents the 
secondary target. 
  4.4.2.2
Non-adap
model is 
that, the f
without b
been exp
case, dos
by 2% an
fractions 
boost allo
fraction s
limit on h
boost epo
volume i
treatment
tumor an
doses for
feasible f
 
For CER
are re-sc
main stag
fraction 
Using the R
tive and ad
solved in th
reedom gen
oost, and th
lained throu
es received 
d the treatm
in the main 
ws dividing
ize limit on
ealthy tissu
ch is delive
s updated af
 plan into at
d at least 13
 the remaini
ractions in t
RLung case
aled down b
e, 25 of tho
25 for non-
atio Model
aptive treatm
e re-optimiz
erated by no
e extra freed
gh the result
from the opt
ent plan is d
stage, the re
 the remain
 the tumor a
es. The dose
red in 10 fea
ter fraction 2
 most 12 fra
 fractions to
ng plan are 
he adaptive 
, the doses r
y 0.5% and
se 36 fracti
adaptive pla
 in the Opti
ent plans fo
ation and th
n-adaptive 
om created
s in Table 4
imization in
ivided into 
-optimizatio
ing plan into
nd at least 1
s for the rem
sible fractio
5 and the re
ctions to sa
 satisfy the m
re-scaled do
planning op
eceived from
 the treatme
ons are deli
nning optim
58 
mization 
r both test c
e results are
planning op
 by adaptatio
.3, apply to 
 the beginni
34 feasible 
n for non-a
 at most 10 
1 fractions t
aining plan
ns. For adap
-optimizati
tisfy the min
aximum he
wn by 3.7%
timization. 
 the optim
nt plan is d
vered. Then
ization wit
ases are als
 re-scaled if
timization w
n in the re-
the results i
ng of the tre
fractions. Af
daptive plan
fractions to
o satisfy the
 are re-scal
tive planni
on allows di
imum fracti
althy tissue
 and the sec
ization in th
ivided into
, the treatme
h boost, an
o generated 
 necessary (
ith boost ov
optimization
n Table 4.5 
atment are 
ter deliverin
ning optimi
 satisfy the m
 maximum 
ed down by 
ng optimiza
viding the r
on size limi
 fraction siz
ond epoch i
e beginning
 36 feasible
nt plan is r
d the compu
where the r
Table 4.5). N
er optimiza
, which has
too. For Lun
re-scaled do
g 25 of tho
zation with 
inimum 
fraction size
0.5% and th
tion, the tum
emaining 
t on the resi
e limit. The
s delivered i
 of the treat
 fractions. I
e-optimized
ted doses a
atio 
ote 
tion 
 
g1 
wn 
se 34 
 
e 
or 
dual 
 
n 12 
ment 
n the 
 after 
llow 
 59 
dividing the remaining plan into at most 15 and at least 16 fractions in order to satisfy the 
minimum and the maximum fraction size limits, respectively. These doses are re-scaled down by 
5% and the remaining treatment plan is delivered in 15 feasible fractions. For the adaptive 
planning optimization, the doses received from the re-optimization allow dividing the remaining 
plan into at most 17 and at least 18 fractions. These doses are re-scaled down by 2% and 17 
feasible fractions are delivered in the second epoch.   
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Table 4.5: No Adaptation vs. Two-Epoch Adaptation Results for Lung1 and CERRLung Test 
Case (Ratio model is solved in the optimization and the results are rescaled if necessary, bold 
and highlighting signifies numbers referenced in the text.) 
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Figure 4.4 compares the average tumor dose and the number of fractions delivered in non-
adaptive and adaptive plans for both test cases. For Lung1 case, Figure 4.4(a) shows that 
adapting the treatment plan once adds 3 more fractions to the overall treatment received by 
optimization without boost and boosts the average tumor dose from 71.6 Gy to 78.3 Gy which 
corresponds to a 6.7 Gy (9.4%) increase. Compared to the non-adaptive planning optimization 
with boost, adaptation improves the average tumor dose from 73.4 Gy to 78.3 Gy corresponding 
to a 4.9 Gy (6.7%) gain while adding 2 more fractions to the overall treatment. The improvement 
in the treatment outcomes by adaptation is illustrated by the CERRLung case results presented in 
Figure 4.4(b). Adapting the treatment plan once adds 2 more fractions to the overall treatment 
received by non-adaptive planning optimization with boost and boosts the average tumor dose 
from  84.2 Gy to 88.5 Gy corresponding to a 4.3 Gy increase (5.1% gain). This gain gets 
significantly bigger when the adaptive planning results are compared to the optimization without 
boost results where the average tumor dose is boosted by 12.6 Gy (16.6%) and the number of 
fractions given in the treatment increased by 6.   
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 (a) Lung1 Case      (b) CERRLung Case 
Figure 4.4: Comparison of Treatment Outcomes When the Ratio Model is solved in the 
Optimization 
 
The detailed dose statistics for each structure in non-adaptive and adaptive plans for Lung1 and 
CERRLung case are presented in Appendix B and C, respectively. The results show that both 
cumulative and fraction size dose limits for all structures are satisfied in the computed plans. 
 
4.4.3 Three-Epoch Adaptation Results 
It is an interesting question to investigate whether the tumor doses received from two-epoch 
adaptation would improve by acquiring another image of the patient and adapting the plan at 
some point during the first 25 fractions. In addition, the extended time in second epoch (i.e. the 
second epoch includes 12 and 17 fractions for Lung1 and CERRLung case, respectively, as 
Table 4.3 indicates) allows additional adaptation before the treatment ends.  
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twice after fraction 25 and 30 for Lung1 case where the residual tumor shrinks with different 
rates after fraction 25. The average tumor dose achieved from two-epoch adaptation improves by 
1.5 Gy and 2.2 Gy with 10% and 30% tumor shrinkage rates, respectively. For these cases, the 
number of fractions delivered in the treatment increased by 1. With residual tumor shrinking 
50%, 3 more fractions are added to the treatment, and the average tumor dose is boosted from 
78.7 Gy to 84.2 Gy indicating a boost of 5.5 Gy. Moreover, compared to 73.4 Gy received from 
non-adaptive planning optimization with boost, this corresponds to a 15% gain. The results in 
Figure 4.6(a) illustrate that the amount of gain obtained from adapting the plan after fraction 30 
is sensitive to the rate the residual tumor shrinks after fraction 25. 
 
Figure 4.6(b) draws the same conclusions from the results on adapting the treatment plan after 
fraction 25 and 30 for CERRLung case. With 50% shrinkage, the average tumor dose achieved is 
enhanced from 88.9 Gy to 93.6 Gy corresponding to a 4.7 Gy increase while two additional 
fractions are delivered in the treatment. Compared to the 84.9 Gy received from non-adaptive 
planning optimization with boost, a 10.2% gain is accomplished by adapting the plan after 
fraction 30. 
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(a) Lung1 Case                          (b) CERRLung Case 
Figure 4.6: Two-Epoch Adaptation (Adapting after Fraction 25) vs. Three-Epoch Adaptation 
(Adapting after Fraction 25 and 30) with Residual Tumor after Fraction 25 Shrinking with 
Different Rates (%) (Uniform fractionation model is solved in the re-optimization.) 
 
The reason behind the improvement by later adaptation is related to the extra freedom created in 
the re-optimization. When more tumor points are removed from the residual tumor after fraction 
30 for both test cases, the minimum fraction size limit constraints on those points are dropped 
from the re-optimization formulation because the cumulative limits on those points have already 
been fulfilled. This relaxes the optimization model and creates more freedom to take advantage 
of in the rest of the plan. In contrast, with the earlier adaptation, fractionation constraints on 
those points are not dropped from the re-optimization since they have not received their 
minimum cumulative dose by that time. Therefore, this prevents relaxing the model and does not 
create necessary freedom for achieving significant improvement by adapting the plan early.  
Note that re-planning the treatment plan at later stages of the treatment (e.g. during the 
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formulation solved at later adaptation points does not include any minimum cumulative dose 
constraint on the secondary target and removed tumor points. For example, one feasible solution 
for re-optimization after fraction 25 would be the solution with 0 beamlet intensity values and 
N=0 since this solution preserves the homogeneous tumor dose distribution achieved during the 
first 25 fractions and satisfies the residual cumulative dose constraints on healthy tissues and 
fraction size dose constraints on all tissues.  
 
However, for the re-optimization formulation solved at a later adaptation point after fraction 30, 
the same solution (0 beamlet intensities and N=0) might not be feasible for the re-optimization 
because the delivered dose to the tumor by fraction 30 could be inhomogeneous in spite of 
maintaining tumor dose homogeneity over the course of the treatment (constraint set (4.18) in 
Figure 4.1).  Although this is the case, there still exists a feasible solution defined as the 
remaining part of the plan after fraction 30 determined by the re-optimization after fraction 25 
(e.g. the plan for the last 12 of the 17 fractions in Epoch 2 computed by the re-optimization after 
fraction 25 is feasible for the re-optimization formulation solved after fraction 30 for CERRLung 
case). Note that this feasible solution may result in higher tumor cumulative dose homogeneity 
than the prescribed level (> 0.95), because some of the points from the residual tumor after 
fraction 25 are removed due to the tumor shrinkage after fraction 30. As a result, due to existence 
of at least one feasible solution for the re-optimization after fraction 25 or 30, the potential 
infeasibility of the subsequent optimization problems at later epochs of re-planning is not an 
issue in the proposed methodology. 
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4.4.4 Three-Epoch Cases Using the Ratio Model in the Re-Optimization 
Three-epoch adaptation experiments for the more interesting case of adapting after fraction 25 
and 30 by solving the ratio model (rescaling results if necessary) in the re-optimization are also 
performed. The results for Lung1 and CERRLung case are summarized in Figure 4.7(a) and (b), 
respectively. The details of these results are given in Appendix H and I demonstrating that both 
cumulative and fraction size dose limits for all structures are satisfied in the twice adapted plans. 
When the residual tumor shrinks with 10% and 30% for Lung1 case, the average tumor dose 
received by two-epoch adaptation is boosted by 2 Gy while an additional fraction is given in the 
overall treatment. With 50% shrinkage, 4.3 Gy increase is achieved whereas 2 more fractions are 
added to the overall treatment. In addition to these results, three-epoch adaptation results for 
CERRLung case show a similar improvement in one time adaptation results in Figure 4.7(b). 
With 50% shrinkage, the average tumor dose received from two-epoch adaptation increased from 
88.5 Gy to 94.9 Gy corresponding to a 6.4 Gy increase whereas 3 fractions are added to the 
overall treatment.  
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(a) Lung1 Case                                             (b) CERRLung Case 
Figure 4.7: Two-Epoch Adaptation (Adapting after Fraction 25) vs. Three-Epoch Adaptation 
(Adapting after Fraction 25 and 30) with Residual Tumor after Fraction 25 Shrinking with 
Different Rates (%)(The ratio model is solved (the results are rescaled if necessary) in the re-
optimization.) 
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5 Biologically Guided IMRT Optimization with Fraction Constraints 
5.1 Background and Significance 
Adaptive radiation therapy based only on geometric changes in the tumor does not exploit 
modern imaging science fully. The frontier of treatment now is generating radiation therapy 
plans that can act on the information acquired on tumor biology (Kim and Tome, 2006; Ling and 
Li, 2005). The initial tumor biological information and the changes in the tumor biology over the 
course of the treatment can be demonstrated using modern methods of physical, functional and 
molecular imaging (Titz and Jeraj, 2008; Stewart and Li, 2007).  
 
Historically, the internal structure (biology) of a tumor in the individual was unknown, leading to 
guidelines that recommend homogeneous dose distributions of doses across target (ICRU Report 
#62, Goitein 1986). However, recent pathologic analysis of tumor specimens from surgery and 
physiologic studies of animal models reveal a complicated tumor structure where the biological 
elements, e.g. hypoxia, proliferation or drug concentration, are not distributed homogeneously 
across the tumor (Levin-Plotnik and Hamilton, 2004; Sovik et al., 2007; Chen et al., 2007). 
These biological elements are related to the tumor point sensitivity defined as the biological 
responses (sensitivity) of the points to radiation. 
 
Tumor hypoxia (low oxygenation) is a well-known biological cause of resistance to radiation and 
can be quantified by using recent molecular and functional images. Hypoxic (low-oxygenated) 
tumor regions are resistant to radiation whereas well-oxygenated tumor regions are sensitive to 
radiation. Identifying the resistant and sensitive tumor regions based on their oxygenation levels 
motivates designing Biologically Guided Radiation Therapy (BGRT) plans that realign the 
 71 
radiation delivered across the tumor with the new information on tumor biology in order to yield 
more effective plans achieving higher tumor control. 
 
In BGRT, the dose at each tumor point can be classified as follows.  
 Tumor physical dose is the dose deposited from all beamlets to each tumor point 
 Tumor biological dose is the effective dose received at each tumor point due to the tumor 
point sensitivity (Note that, the tumor biological dose can be at most as great as the tumor 
physical dose)  
 
Figure 5.1 demonstrates the effective biological dose received at tumor points across conditions 
of different oxygenation given the same physical dose. As illustrated, as the oxygenation level 
decreases (extreme hypoxia), the resistance to the radiation increases; therefore, the biological 
dose received at tumor points reduces significantly. This motivates BGRT plans to deliver higher 
dose to the hypoxic tumor points in order to prevent cold spots (under-dosed regions) in tumor.   
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Figure 5.1: Tumor Physical Dose vs. Tumor Biological Dose across Conditions of Different 
Oxygenation 
 
This research develops optimization models that take biological information, e.g. tumor hypoxia, 
into account in the treatment planning optimization. Developing mathematical models and 
testing them is a challenging problem since BGRT is a new area. Quantification of biological 
data is new and still in development and not much known on modeling issues. Also, there are no 
known, openly available datasets on tumor biology outside of the clinical institutions yet. This 
dissertation research is one of the first attempts that deal with modeling and testing biological 
optimization concepts without losing significant relevancy to clinical practice.  
 
5.2 Biological Optimization Models 
5.2.1 Modeling Notation and Assumptions  
The previous notation introduced for secondary targets in Chapter 2 is modified in order to 
handle multiple secondary targets. Let V denote the set of secondary targets. Let totalvl  and 
daily
vl  
Extreme
Hypoxia
Hypoxia Intermediate
Oxygenation
Full
Oxygenation
Physical Dose Biological Dose
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represent the minimum cumulative and fraction size dose limit for all the points in secondary 
target Vv , respectively.  
 
Up to this point, all the tumor doses computed in Chapter 2 through Chapter 4 were physical 
doses where no information was known on the biology. In this chapter, the tumor dose will be 
specifically classified as tumor physical or tumor biological dose. 
 
Note that, the equation (1) in Section 2.2 presented the physical dose computation for each tumor 
point iœT as 


Jj
jiji xad . The physical tumor dose di for each tumor point i will be adjusted by 
its tumor point sensitivity in order to compute the actual biological dose received at that point. 
Tumor point sensitivity can represented as:  
li: adjustment factor due to the loss of effect with hypoxia for each point iœT (0<li≤1) 
 
Then let bid be biological dose received at tumor point iœT computed by multiplying tumor point 
i’s sensitivity (li) by the physical dose deposited to point i (di) as follows (Titz and Jeraj 2008). 
  ii
Jj
jiji
Jj
jiji
b
i dxaxad   

 Ti                                    (5.1) 
 
It is assumed that sensitivity needs to be accounted for only on tumor points and the tumor point 
sensitivities (l) do not change over the course of the treatment in static (non-adaptive) plans. 
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5.2.2  Biological Uniform Fractionation Model  
The biological uniform fractionation model developed is a variant of the uniform fractionation 
model presented in Section 2.5. The model maximizes average tumor biological dose (5.2) over 
non-negative bid  subject to cumulative average and upper dose limit constraint sets (5.3) through 
(5.4) on healthy tissues, cumulative minimum dose limit constraint set (5.5) on secondary 
targets, tumor dose homogeneity limit (5.6), dose consistency constraint (5.7) and the integer 
fraction size dose constraint sets (5.8) through (5.10). In the rest of this section, the major 
differences between the uniform fractionation model of Section 2.5 and the biological uniform 
fractionation will be highlighted.  
 
|T|/d
Ti
b
i 



maximize                        (5.2) 
 
kk
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i Hd
k


 Kk                     (5.3) 
 
total
ki ud   kHi,Kk                     (5.4) 
 
total
vi ld   vSi,Vv                                (5.5) 
 
min
imin
DdD   Ti                      (5.6) 
 
min
i
Dd   vSi,Vv                         (5.7) 
 Nld
daily
vi   vSi,Vv                     (5.8) 
 Nld
daily
tumor
b
i   Ti                                    (5.9) 
 Nud
daily
ki    kHi,KKk                   (5.10) 
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Biological objective function 
The objective function of the optimization model (5.2) maximizes average biological dose across 
the tumor in contrast to the previous objective of maximizing average tumor physical dose in the 
uniform fractionation model.      
        
Tumor physical dose homogeneity 
One of the open questions in biological optimization is whether homogeneity limits should be 
enforced on tumor physical or biological doses. In the case of enforcing a homogeneity limit on 
tumor physical doses, the constraint set (5.6) would remain the same. In addition, that constraint 
set would allow capturing the maximum tumor physical dose (Dmin/a) which then would be used 
as the right hand side of the dose consistency constraint set (5.7) (Recall that, the dose 
consistency constraint ensures that the maximum dose received at secondary targets does not 
exceed the maximum tumor physical dose).    
 
Furthermore, in order to effectively react to the more severe hypoxia in tumor, one could choose 
lower homogeneity value (e.g 80. ) which would give freedom to the model in optimizing 
tumor physical dose distribution. 
 
Tumor biological dose homogeneity 
If one desires to impose a homogeneity limit on tumor biological doses rather than tumor 
physical doses, constraint set (5.6) would be replaced with constraint set (5.11) in the 
optimization model, where bminD  is a continuous variable defining the minimum tumor biological 
dose.  
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
b
minb
i
b
min
DdD   Ti          (5.11) 
 
Enforcing constraint set (5.11) captures the maximum tumor biological dose but not the 
maximum tumor physical dose which makes the dose consistency constraint harder to model. 
Exact modeling of this constraint requires introducing binary variables resulting in a much more 
computationally expensive optimization model. To avoid this, an approximate method is used to 
estimate the maximum tumor physical dose by dividing the maximum biological dose by 
hypoxic adjustment factor l of the second most insensitive region value. By using this 
estimation, the dose consistency constraint (5.7) is replaced with the following dose consistency 
constraint set (5.12) where ˆ  denotes the hypoxic adjustment factor of the second most 
insensitive tumor region value. 
 

ˆ
/Dd
b
min
i   vSi,Vv              (5.12) 
 
Tumor fraction size requirement 
Lastly, the tumor fraction size dose constraint set (5.9) is stated in terms of biological dose in the 
optimization model. This imposes a lower dose requirement on tumor biological doses per 
fraction rather than tumor physical doses per fraction. Controlling the minimum biological dose 
achieved per fraction would increase the probability of cure. 
  
In summary, the biological uniform fractionation model is a single integer variable mixed-integer 
linear programming model producing uniform plans over N fractions. The integer variable N in 
the fraction size dose constraint sets guarantees that the cumulative plan can be divided into 
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integer number of fractions where all the fraction size dose limits on healthy tissues and 
secondary targets, and biological fraction size dose limit on all tumor points are satisfied. 
 
5.2.3 Biological Adaptive Planning Optimization Methodology 
An adaptive planning optimization methodology is also developed that re-plans treatment plans 
in response to the changes in the tumor point sensitivities (l). This methodology follows the 
same steps summarized in Section 4.3. Although the adaptive planning optimization 
methodology given in Section 4.3 considers adapting the treatment plan M times, here only two-
epoch adaptation (M=1) would be investigated. The major reasons behind this choice are two-
epoch adaptation in Chapter 4 gave excellent results (lessening the need to adapt more than once) 
and adapting more than once to the changes in the sensitivities would require more data 
generation for testing which could not have been done realistically since little is known on 
quantifying the sensitivity change.  
 
In the proposed adaptive approach, the treatment plan is adapted after delivering a sequence of 
fractions by incorporating the latest tumor point sensitivity information (l) in order to achieve 
the best IMRT design for the overall treatment and for each fraction. The treatment plan is first 
optimized against both cumulative and fraction size dose limits based on the biological image at 
the beginning of the treatment by solving the biological uniform fractionation model presented in 
the previous section. The optimized treatment plan is divided into N fractions and the first N1 are 
delivered in Epoch 1.  
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After delivering the first epoch, a new biological image showing the latest hypoxia information 
is acquired and the tumor point sensitivities (l) are updated. In addition to this, the residual 
cumulative dose limits for all tissue points (right hand side of the constraints in the previous 
section) are updated by subtracting the dose delivered from against their cumulative dose limits 
in Epoch 1. Then, the remaining treatment plan is re-optimized against residual cumulative and 
fraction size dose limits by solving the model in the previous section (with integer variable N2) to 
compute N2 fractions to be delivered in Epoch 2. The steps taken in this adaptive approach are 
summarized with a flow chart in Figure 5.2.  
 
 
 
 
 
  
 
 
 
 
 
 
Figure 5.2: Summary of Biological Adaptive Optimization Approach 
 
Solve the biological uniform fractionation model with 
initial tumor point sensitivities (l). 
Deliver the first N1 fractions in the first epoch. 
Acquire a new biological image and update tumor 
point sensitivities (l).  
 
Adjust right hand side of the constraints by subtracting 
dose already delivered from cumulative dose limits. 
Solve biological uniform fractionation model with 
adjusted right hand sides and an integer variable N2. 
Deliver N2 fractions in Epoch 2. 
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5.2.4 Tumor Control Probability: Measure of Effectiveness   
In the previous chapters, the effectiveness of the computed plans is measured by the tumor dose 
statistics such as maximum, minimum and average tumor physical doses. With the tumor point 
sensitivity information (l), it is not possible to compute tumor biological dose statistics and use 
them instead to evaluate treatment plans. A further step to more accurately measure the 
biological effectiveness of plans would be to convert the tumor physical dose distributions with 
the tumor point sensitivity information (l) into a commonly used biological objective in the 
literature as Tumor Control Probability (TCP) (Ruggieri et al., 2010; Yang and Xing, 2005). 
 
TCP is defined as the probability that all the cells in tumor are inactivated after a course of 
treatment; therefore, it estimates the success of the treatment. Using TCP provides a fair 
comparison between plans since it is impacted by both average and the minimum biological 
doses. For example, although a treatment plan achieving a higher average biological dose seems 
to be a more effective plan, it could result in being a less successful treatment due to under-dosed 
points with a smaller minimum biological dose. However, the effect of both achieved average 
biological dose and the minimum biological dose is captured in TCP calculation; therefore, 
allows a fair comparison between treatment plans.  
 
Equation (5.13) computes TCP by multiplying TCPi across all tumor voxels. TCPi represents the 
probability that all the cells in voxel i are inactivated for Ti . 



|T|
1i
iTCPTCP                       (5.13) 
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TCPi is a function of initial number of cells in each tumor voxel, denoted as n, and the surviving 
fraction of cells at voxel i (  iN dS ) after di physical dose is delivered over N fractions. The 
effect of hypoxia is included in the surviving fraction formula in (5.15). Here, n is equal to tumor 
voxel size (mm3) times tumor cell density (cells/mm3). TCPi is computed in equation (5.14) as 
follows. 
  iNi dnSexpTCP   Ti           (5.14) 
 
The  iN dS  at each tumor voxel i is computed by the equation (5.14) (Ruggieri et al., 2010). The 
first term of the exponential function is the cell killing effect over N fractions whereas the second 
term is the re-population effect (i.e. tendency of tumor cells to regrow over the course of the 
treatment) over N fractions. Here, re-population parameters are denoted as following: Dt is the 
inter-fractional time interval, Teff is effective clonogenic doubling time, Td is delay time in 
clonogenic accelerated repopulation.  
    

 

  d
eff
i
iiiiN Tt1NT
2ln
N
ddexpdS   Ti          (5.15) 
 
The tumor hypoxia at each voxel i is included in equation (5.15) by the radiosensitivity 
parameters αi and βi. Here, αi= αo*li and βi= βo*(li)2  are used (Titz and Jeraj, 2008) where αo 
and βo are  radiosensitivity parameters at well-oxygenated state.  
 
The formula given in equation (5.15) computes surviving fraction assuming same tumor point 
sensitivity over N uniform fractions. There is a need to use a slightly modified formula in case of 
tumor point sensitivity change. Equation (5.16) computes the overall surviving fraction for tumor 
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voxel i after 1id  physical dose is delivered over N1 fractions in the first epoch taking into account 
initial hypoxia and 2id  physical dose is delivered over N2 fractions in the second epoch taking 
into account updated hypoxia.  Since the tumor point sensitivity (li) changes between first and 
second epoch, radiosensitivity parameters  1i1i ,  and  2i2i ,  are defined for the first and 
second epoch, respectively. The first and second term of the exponential function in equation 
(5.16) is the cell killing effects over the first and second epoch, respectively, whereas the last 
term incorporates the repopulation effect into the formula.   
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(5.16) 
 
5.3 Generating a Test Case 
5.3.1 The Need 
Testing biological optimization models requires cases where the tumor hypoxia information is 
known. Unfortunately, such desired test cases are not publicly available, because clinical studies 
on hypoxia imaging are new and not many institutions have performed these studies. In addition, 
it is always challenging to get datasets from research institutions due to their very strict rules on 
sharing patient data. 
 
One way to obtain the tumor hypoxia information might be randomly generating the tumor point 
sensitivities (l) across the tumor. However, this approach would not have much clinical validity 
and would conflict with this dissertation research’s efforts on testing optimization models with 
cases simulating real practice. In order to maintain clinical relevancy as much as possible, the 
approach (Section 5.3.3) of inserting artificial hypoxia information based on a published test case 
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extracted from CERR website (“CERR: A Computational Environment for Radiotherapy 
Research”) was adopted.    
 
5.3.2 Description of the CERR Head and Neck Test Case 
An anonymized head and neck case presented on CERR website is used as a basis for the test 
case. Figure 5.3 displays an example slice outlining structures under interest. With clinical 
guidance, it was decided to treat Target1, Target2, and Target3 as secondary targets and insert an 
artificial primary target (tumor) inside Target1 (shown as dashed circle). Note that, the artificial 
primary target is stretched in z-direction (≤) to have a 3-dimensional, more realistic tumor shape 
of a prolate sperhoid (i.e. shape of a football).  
 
Table 5.1 shows the number of sampling points used for the optimization and the influence 
matrix density for each structure in the head and neck test case along with the selected beam 
angles. The number of sampling points for each structure is determined after doing 
experimentation with different sampling densities. During experimentation, the dose-volume 
histograms (DVHs) using all possible points are created from the optimization results based on 
different sampling densities, and a sampling density that creates acceptable DVHs was selected 
for each structure. The influence matrix for this test case is generated using radiation therapy 
software system CERR.  
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primary target, secondary targets and healthy tissues. All of the points in each structure are 
subject to its corresponding fraction size limit.  
 
Table 5.2: Prescription for the Head and Neck Test Case (“pDose” refers to tumor physical dose, 
“bDose” refers to tumor biological dose) 
Structure Structure Description 
Head and Neck Case 
Cumulative Dose 
Objective/Limit (Gy) 
Fraction Size 
Dose Limit 
(Gy) 
Tumor Primary Target 
Maximize avg. 
pDose/bDose ≥ 1.80 
90
p(b)Dose tumor max.
p(b)Dose tumor min. .
Target1 Secondary Target 100% ≥ 60 ≥ 1.80 
Target2 Secondary Target 100% ≥ 60 ≥ 1.80 
Target3 Secondary Target 100% ≥ 54 ≥ 1.65 
Mandible Healthy Tissue Avg. dose ≤ 40 100% ≤ 72 ≤ 2.10 
Brainstem Healthy Tissue 100% ≤ 58 ≤ 2.10 
Not Otherwise 
Specified Tissue Healthy Tissue 100% ≤ 80 ≤ 2.10 
Spinal Cord Healthy Tissue 100% ≤ 50 ≤ 2.10 
 
5.3.3 Calibrating Tumor Point Sensitivities (l) 
An human PET image acquired prior to the treatment and the mathematical relationships from a 
recent study (Titz and Jeraj, 2008) are used in order to generate l’s in the simulated tumor. 
Figure 5.4(a) shows the PET image with tumor hypoxia information (in color) where different 
colors indicate different hypoxia levels. As Figure 5.4(b) illustrates, the hypoxia distribution of 
the inserted artificial primary target on a single slice (the example slice in Figure 5.3) is 
approximated with the help of the hypoxia map on the PET image given in Figure 5.4(a) where 
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The OMF values in Figure 5.5(b) are actually equal to rescaled OER to [0-1] range. These OMF 
values are used as tumor point sensitivities (l) in the biological optimization. 
 
The OMF values (l) for each tumor region used in the computational experiments are 
summarized in Table 5.3. The details including the approximate SUV range for each tumor 
region, the selected SUV values and their pO2 values corresponding to the OMF values in each 
base case are given in Appendix J. As Table 5.3 demonstrates, only the hypoxia level in red 
region differs between two base cases, where the red region is more hypoxic in the second base 
case with a lower OMF value (OMF=0.77 vs. OMF=0.82). Besides the OMF values, the table 
presents the point count and matrix density for each tumor region.  
 
Table 5.3: Two Base Cases Used in the Experiments (OMF=Oxygen-Modification Factor, 
l=Tumor Point Sensitivities) 
Tumor 
Regions 
First Base Case Second Base Case Point Count 
Matrix 
Density OMF=l OMF=l 
Red 0.82 0.77 94 85% 
Yellow 0.88 0.88 186 85% 
Green 0.91 0.91 749 85% 
Light Blue 0.92 0.92 710 86% 
Dark Blue 0.98 0.98 789 87% 
 
5.3.4 Generating Biological Change in Tumor Point Sensitivity (l) 
The initial l values presented in Table 5.3 may change as the treatment evolves. However, how 
to quantify this change as a function of delivered dose is unknown, and more clinical research is 
required to understand how tumor point sensitivities change throughout the treatment. Currently, 
there are published studies in the literature giving insight on the direction of the change 
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(Eschmann et al., 2007; Popple et al., 2002; Titz and Jeraj, 2008; Lee et al., 2009; Rischin et al., 
2001; Hall, 1994). These papers indicate that the hypoxic cells can absorb oxygen and change 
their state to oxygenated. This phenomenon is known as re-oxygenation of tumor cells.  
 
Following the re-oxygenation phenomenon, the tumor regions in the generated test case are 
expected to get more oxygenated; therefore, the l values (=OMF) in Table 5.3 are likely to 
increase over the course of the treatment and get closer to 1.0 (OMF value for well-oxygenated 
state). Since the rate of the re-oxygenation is not known, it is assumed that the all tumor regions 
will close their gap by a fraction b at a specific point in time, referred as adaptation/re-
optimization point, denoted as R. For example, assuming all tumor regions are one quarter re-
oxygenated after delivering R=25 fractions, b would be equal to 0.25. The following formula 
computes the updated l, denoted as lu,  at the adaptation point. 
lu = l + (1-l)*b              (5.18) 
 
5.4 Computational Experiments 
Computational experiments on biological optimization compared various approaches by testing 
on the cases presented above. Section 5.4.1 will present physically and biologically optimized 
plans computed for the datasets above to assess the benefit of taking the initial tumor point 
sensitivity (l) information into account in the treatment planning optimization. To illustrate the 
importance of modeling fractionation constraints explicitly in the optimization, Section 5.4.2 will 
compare plans optimized against cumulative dose constraints alone and plans optimized against 
both cumulative and fraction size dose constraints. Furthermore, Section 5.4.3 will show results 
from re-planning the treatment plans to the changes in the tumor point sensitivity to realize if 
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gains in the treatment outcomes can be achieved. All these plans are computed with two different 
tumor hypoxia scenarios summarized in Table 5.3.   
  
For the TCP computation throughout the computational experiments, the following parameters 
are used based on a published paper (Ruggieri et al., 2010): Dt=1 day, Teff=3 days, Td=0 days, 
ao=0.35Gy-1 and bo=0.035Gy-2.  The number of cells in each tumor voxel (n) is equal to 
1,200,000 (voxel size (12 mm3)*cell density (105 cells/mm3)) where the used cell density of 105 
cells/mm3 is an acceptable value between 104 cells/mm3 (Ruggieri et al., 2010) and 106 
cells/mm3 (Titz and Jeraj, 2008). The TCP calculation for the plans presented in Section 5.4.1 
and Section 5.4.2 uses the surviving fraction equation (5.15) whereas the TCP calculation for the 
plans given in Section 5.4.3 uses the surviving fraction equation (5.16). 
 
5.4.1 Physically Optimized Plan Results vs. Biologically Optimized Plan Results	
Physically and biologically optimized plans can be defined as follows.  
 Physically optimized plans: Plans computed ignoring tumor biology in the optimization, 
but biologically scored after optimization using the tumor point sensitivity (l) 
 Biologically optimized plans: Plans computed considering tumor biology in the 
optimization 
 
Physically optimized plans are generated by solving the uniform fractionation model presented in 
Section 2.5. Biologically optimized plans are generated by solving the biological uniform 
fractionation model presented in Section 5.2.2. All the physical and biological plans were 
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cumulative and fraction size dose achieved by biologically optimized plan with physical 
homogeneity raises the TCP value by 0.08 (0.66 vs. 0.74).  
 
By contrast, enforcing biological homogeneity in biologically optimized plan reduces average 
tumor physical and biological dose substantially (Figure 5.6(a)). Comparing against the 
physically optimized plan, the average biological dose decreased by 4.4 Gy (78.9 Gy vs. 74.5 
Gy). The main reason behind the significant reduction in average biological dose is the 
optimization keeps the maximum biological dose lower in order to maintain tumor biological 
dose homogeneity. The restriction of the average biological dose in biologically optimized plan 
with biological homogeneity reduced the TCP significantly from 0.66 to 0.47 corresponding to a 
0.19 decrease (Figure 5.6(b)). 
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5.7(a) and (b), although the biological plan achieves less average tumor dose (81.6 Gy vs. 78.8 
Gy), it increases the minimum tumor biological dose from 63.5 Gy to 64.8 Gy and the minimum 
tumor biological fraction size dose from 1.67 Gy (63.5 Gy/38 fractions) to 1.71 Gy (64.8 Gy/38 
fractions). Since TCP is very sensitive to the increase in the minimum biological dose, these 
increases in both biological cumulative and fraction size dose were reflected in 0.07 raise in TCP 
(0.63 vs. 0.70).     
  
As the results in Figure 5.7(a) and (b) illustrate, biologically optimized plan with biological 
homogeneity again lowers the TCP obtained by physically optimized plan significantly which is 
in line with the first base case results. The biological optimization keeps the maximum tumor 
biological dose lower due to the homogeneity requirement on tumor biological doses. This 
restricts the average tumor biological dose over 6 Gy (81.6 Gy vs. 75.2 Gy). This significant 
decrease in average tumor biological dose reduced the TCP value from 0.63 to 0.27.  
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Figure 5.7: Summary of Physically Optimized Plans vs. Biologically Optimized Plans at Higher 
Red Hypoxia and 0.8 Tumor Dose Homogeneity (*Physically optimized plans are biologically 
scored with initial tumor point sensitivities.) 
 
The results presented on both cases in Section 5.4.1.1 and 5.4.1.2 demonstrate the potential 
benefit of incorporating biological information into the treatment planning optimization, and 
therefore, prove the concept of possible clinically significant gains that might be achieved by 
biological optimization. Furthermore, the importance of deciding whether to enforce 
homogeneity requirement on tumor physical or biological doses is demonstrated by the results, 
and enforcing tumor physical dose homogeneity in the optimization is preferred throughout the 
computational experiments due to allowing better plans.    
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It is noteworthy to state that although TCP is a good measure of biological effectiveness, it was 
discovered during the computational experiments that it could be volatile for some instances. 
This volatility is further illustrated in Appendix M. 
 
5.4.2 Illustrating the Need to Include Fractionation Constraints Explicitly in the 
Optimization 
In addition to the improvement in TCP obtained by biological optimization, satisfying fraction 
size requirements on secondary targets in the computed plans helps achieve better cure for these 
structures. Figure 5.8(a) and (b) illustrates the importance of explicitly including integer 
fractionation constraints into both physical and biological optimization. The physically or 
biologically optimized feasibly fractionated plans already presented in Section 5.4.1.1 and 
5.4.1.2 were optimized against both cumulative and fraction size dose constraints. For 
comparison purposes, physically optimized cumulative plans are generated by solving the LP 
formulation in Section 2.3.1 and biologically optimized cumulative plans are generated by 
solving the biological uniform fractionation model in Section 5.2.2 ignoring fraction size 
constraints. Note that, both physical and biological cumulative plans are optimized against 
cumulative dose constraints alone.  
 
The graphs in Figure 5.8(a) and (b) show the control probabilities for the secondary targets 
including Target1, Target2, and Target 3 as well as the primary target across all computed plans. 
The cumulative plans are divided into integer number of fractions satisfying all the healthy tissue 
maximum fraction size requirements (e.g. cumulative plans are delivered over 39 fractions). 
Satisfying the healthy tissue fraction size limits come at the expense of violating the minimum 
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fraction size requirements on secondary targets in cumulative plans. This is reflected by 
computing control probabilities for secondary targets by using the same calculations in Section 
5.2.4. Lower cell density (103cells/mm3) is used for secondary target control probability 
computations (Strigari et al., 2008). 
 
As Figure 5.8(a) and (b) show, although the tumor control probabilities are very close to each 
other between cumulative and feasibly fractionated plans, the secondary target control 
probabilities are clinically significantly lower in cumulative plans (e.g. 0.07 vs. 0.92 Target2 
control probabilities for base case 1 and 0.07 vs. 0.95 Target2 control probabilities for base case 
2 achieved in biologically optimized cumulative and feasibly fractionated plans, respectively). 
The reason behind achieving better secondary target control probabilities in feasibly fractionated 
plans is imposing minimum fraction size requirement on secondary targets in the optimization. 
Explicitly including constraints on this requirement ensures higher control probability values for 
secondary targets without sacrificing the tumor control probability values.  
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(a) First Base Case     (b) Second Base Case 
Figure 5.8: Illustrating the Importance of Including Fractionation Constraints in the Optimization 
(“Cumulative” refers to plans optimized against cumulative dose constraints alone, “Feasibly 
Fractionated” refers to plans optimized against both cumulative and fraction size dose 
constraints.) 
 
5.4.3 Results from Re-planning the Biologically Optimized Plans to the Changes in 
Tumor Point Sensitivity (l) 
Treatment plans are adapted to the changes in the tumor point sensitivity (l) by using the 
biological adaptive optimization methodology presented in Section 5.2.3. The initial l values 
used in the adaptive methodology are as same as the l values presented in Table 5.3. For the 
computational experiments in this section, initial l values are assumed to one quarter and one 
half re-oxygenate, closing their gap by b=0.25 and b=0.50, respectively. The updated l values 
are calculated by using equation (5.18). The re-optimization (adaptation) point, denoted as R, 
correspond to after fraction 25 or fraction 30 in the experiments.   
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therefore, the plans still satisfy all their cumulative and fraction size dose limits. In addition, both 
cumulative and fraction size dose limits are maintained in computed adaptive plans since the 
related constraints are explicitly enforced in the optimization.  
 
 
Figure 5.9: Comparison of Treatment Plans across Various Scenarios of Different Re-
optimization Point (R) and Re-oxygenation rate (b) on First Base Case (Each column shows the 
average biological dose with its upper and lower bar indicating the minimum and maximum 
biological doses achieved, respectively. The numbers in bold show TCP values for each plan 
whereas the numbers in parenthesis below average doses indicate the number of fractions 
delivered in each plan.) 
 
Although biological re-scoring due to re-oxygenation helps non-adaptive physically optimized 
plans, non-adaptive biologically optimized plans still do better in terms of TCP as Figure 5.9 
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illustrates. In case of quarter re-oxygenation acquired by a biological image after fraction 25 
(R=25, b=0.25), the biologically optimized plan improves the TCP by 0.06 (0.76 vs. 0.82). For a 
different scenario with halfway re-oxygenation after fraction 30 (R=30, b=0.50), the increase in 
TCP is equal to 0.04 (0.79 vs. 0.83). These increases in TCP by biologically optimized plans are 
achieved by due to the significant raises in the minimum biological doses of the physically 
optimized plans as illustrated in Figure 5.9. 
 
Furthermore, re-optimizing the treatment plan to the changes in the tumor point sensitivity (l) 
produces further gains in TCP. The biological plan is re-optimized in response to quarter re-
oxygenation acquired by an image after fraction 30 (R=30, b=0.25) and improves the TCP by 
0.01 (0.79 vs. 0.80) due to the small increase in average tumor biological dose (78.8 Gy vs. 78.9 
Gy). Similar improvement (0.83 vs. 0.84) is achieved by biologically optimized adaptive plan in 
case of halfway re-oxygenation after fraction 30 (R=30, b=0.50) due to the small increase in 
average tumor biological dose (79.2 Gy vs. 79.3 Gy). As a result, these small improvements in 
TCP obtained by adaptive plans increase the TCP gain over physically optimized plans (0.73 vs. 
0.80 for (R=30, b=0.25), 0.79 vs. 0.84 for (R=30, b=0.50)).  
 
One last note on the results presented in Figure 5.9 is related to the number of fractions delivered 
in each plan. As demonstrated in the Figure, except for (R=25, b=0.50), the number of fractions 
delivered in adaptive plans does not change by re-optimization (i.e. 38 fractions are delivered at 
those scenarios). However, for the specified case, the re-optimization adds a single fraction to the 
treatment resulting in 39 fractions. The increase in the number of fractions lowers the per-
fraction biological effect resulting in a lower TCP of 0.83.  
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Figure 5.10: Comparison of Treatment Plans across Various Scenarios of Different Re-
optimization Point (R) and Re-oxygenation rate (b) on Second Base Case (Each column shows 
the average biological dose with its upper and lower bar indicating the minimum and maximum 
biological doses achieved, respectively. The numbers in bold show TCP values for each plan 
whereas the numbers in parenthesis below average doses indicate the number of fractions 
delivered in each plan.) 
 
Similar to the first base case results presented in the previous section, non-adaptive biologically 
optimized plans improve over non-adaptive physically optimized plans in case of re-oxygenation 
as illustrated in Figure 5.10. In case of the quarter re-oxygenation that occurs at the end fraction 
25 (R=25, b=0.25), the biological plan improves the TCP by 0.03 (0.76 vs. 0.79). For the case of 
halfway re-oxygenation by the end of fraction 30 (R=30, b=0.50), TCP improves from 0.79 to 
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0.81 corresponding to a 0.02 gain. The improvements in TCP are achieved due to the significant 
increases in the minimum tumor biological doses of the physical plans. 
 
As Figure 5.10 demonstrates, biologically optimized adaptive plans raise TCP for all these 
higher red hypoxia (lower OMF) scenarios by a higher magnitude than the improvements seen in 
the previous section. It is also important to note that the average tumor biological doses achieved 
in non-adaptive biologically optimized plans increase by significant amount with the help of re-
optimization in adaptive plans. When an acquired biological image after fraction 25 shows 
quarter re-oxygenation (R=25, b=0.25), re-optimizing the treatment plan to this change improves 
the average tumor biological dose by 1.8 Gy (79.3 Gy vs. 81.1 Gy) resulting in a 0.02 gain in 
TCP (0.79 vs. 0.81). Similarly, re-optimizing the treatment plan after fraction 25 in response to 
the halfway re-oxygenation (R=25, b=0.50) improves the average tumor biological dose by 1.8 
Gy (79.9 Gy vs. 81.7 Gy) and improves the TCP from 0.85 to 0.87.  For the scenario considering 
(R=30, b=0.25), the biological adaptive plan improves the average tumor biological dose 
obtained from non-adaptive biological plan by 1.3 Gy (79.1 Gy 80.4 Gy) resulting in a 0.02 
increase in TCP (0.76 vs. 0.78). Lastly, for (R=30, b=0.50), the average tumor biological dose 
increases by 1.4 Gy (79.4 Gy 80.8 Gy) and the TCP rises from 0.81 to 0.83 corresponding to a 
0.02 gain.  
 
These gains produced by biologically optimized adaptive plans help achieving more significant 
improvements over the physically optimized plans. For example, in case of quarter re-
oxygenation after fraction 25 (R=25, b=0.25), adaptive plan improves TCP of physical plan by 
0.05 (0.76 vs. 0.81). In addition, for (R=30, b=0.25), TCP increases by 0.06 (0.72 vs. 0.78).    
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The results presented in Figure 5.9 and 5.10 demonstrate the importance of when to re-optimize 
(R) and how fast the re-oxygenation occurs (b) for the improvements in TCP obtained by 
biologically optimized adaptive plan. For both first and second base cases, the improvement gets 
its highest values (0.07 for the first base case and 0.06 for the second base case) at a later re-
optimization point (R=30) with lower re-oxygenation rate (b=0.25). The lower re-oxygenation 
rate acquired by a late image in the treatment leaves a longer period of time where the initial 
hypoxia values are used in scoring the physical plans which worsens the results. However, a 
longer period of time with initial hypoxia values favors biologically optimized plans since the 
initial biology information is dealt with in the optimization allowing the opportunity for the 
biological plans to show their superiority.  In contrast, higher re-oxygenation rate imaged earlier 
in the treatment (R=25, b=0.50) reduces the TCP gain by helping physical plans significantly and 
removing opportunities for biologically optimized plans by reducing the period of time that more 
severe hypoxia applies. 
 
Overall, the results presented in Section 5.4.3.1 and 5.4.3.2 show that re-planning the biological 
plans in response to the changes in the tumor point sensitivity (l) provides mathematical gains 
that are enough to be clinically significant. These gains demonstrate the potential benefit of 
adapting the biological plans to the changing tumor biology, and therefore, prove the concept of 
achieving higher TCP by biologically adaptive planning optimization. 
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6 Conclusions and Future Research  
This research investigates the opportunities that could be created in IMRT planning by 
incorporating the changes in the tumor geometry and the initial and changing tumor biology into 
the optimization. Adaptive optimization methodologies were developed that re-optimized the 
treatment plans in response to the changes in the tumor geometry acquired from updated images 
against both cumulative and fraction size dose constraints in order to determine the best design 
for each fraction and the overall treatment.  
 
Using the tumor biology information prior to the treatment, biological optimization models were 
developed that adjusted the radiation delivered across tumor to the sensitivity of tumor points. 
Furthermore, biologically optimized plans were designed which were adaptive to the changes in 
tumor point sensitivity over the course of the treatment.  
 
All the optimization models developed in this research were based on mixed-integer linear 
programming formulations of the problem with single non-negative integer variable for the 
number of fractions. Throughout the research, significant attention was given to the feasible 
fractionation of the treatment plans by explicitly including cumulative and fraction size dose 
constraints in the formulations.  
 
The contributions of this dissertation research are listed as follows. This research: 
 Developed and tested a ratio model with re-scaling approach to deal with fractionation of 
treatment plans 
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 Demonstrated the challenge of fractionating adaptive plans re-optimized against only 
cumulative dose limits using a lung test case simulating real practice  
 Showed clinically significant improvements in tumor doses with re-optimizing treatment 
plans in response to the changes in the tumor geometry over the course of the treatment 
using two lung test cases simulating real practice (Both cumulative and fraction size dose 
limits are satisfied in computed adaptive plans.) 
 Demonstrated significant improvements in tumor control by including initial tumor 
hypoxia information into the optimization on a synthetic head and neck test case 
 Illustrated the need to explicitly enforce integer fraction size dose constraints in such 
biological optimization 
 Showed mathematical gains in tumor control and average tumor doses that are enough to 
be clinically important by adapting treatment plans to the changes in the tumor hypoxia 
throughout the treatment (Both cumulative and fraction size dose limits are satisfied in 
computed adaptive plans.) 
 Displayed the volatility of tumor control probability to the changes in the tumor hypoxia 
values 
 
For future research on adaptive planning optimization with changes in the tumor geometry, the 
currently used tumor homogeneity dose requirement over the course of the treatment can be 
extended by introducing tumor dose homogeneity limit for each epoch which will make the 
computed plans clinically more applicable. Modeling this requirement in the re-optimization 
formulation will make sure that all regions of the tumor receive a homogeneous dose distribution 
not only over the entire treatment but also over each epoch. Another extension of this study 
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might be on improving the quality of the updated plans received from re-optimization. At 
present, the treatment plan is re-optimized based on the latest tumor geometry, so no future 
changes on the tumor geometry are predicted. Information on the future tumor geometry received 
by using a predictive modeling can be incorporated into the re-optimization formulation which 
might improve the plan delivered after adaptation. Lastly, although incorporating dose-volume 
constraints into the optimization increases the computational complexity of the models (Lee et 
al., 2006; Tuncel et al. 2010), the trade-off between the quality of the adaptive plans with dose-
volume constraints and the computational time to generate them should be investigated.  
 
Research on biologically guided radiation therapy planning optimization can be extended in 
several ways. As more test cases with tumor hypoxia information become available in the future, 
the biological optimization models developed in this research can be further tested and the 
improvements in the tumor control can be evaluated. In addition, in parallel to the clinical 
research on quantifying change in the hypoxia with respect to dose, more reliable adaptive 
scenarios could be generated and the proposed adaptive planning optimization methodology 
could be tested with multiple scenarios.   
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APPENDICES 
Appendix A3: No Adaptation vs. Two-Epoch Adaptation Results for the Lung1 Test Case (The 
uniform fractionation model solved in the optimization) 
Structure 
Dose 
Statistics 
(Gy) 
No 
Adaptation 
(No Boost)
No Adaptation (with 
Boost) Two-Epoch Adaptation 
Total Main Stage 
Boost 
Stage Total 
Epoch 
1 
Epoch 
2 (with 
Boost) 
Total 
Tumor 
Max. 
Dose
75.0
[2.14]
53.6
[2.14]
24.3
[2.43] 75.3 
53.6 
[2.14] 
29.6 
[2.47] 80.5 
Min. 
Dose
71.3
[2.04]
50.9
[2.04]
20.0
[2.00] 71.6 
50.9 
[2.04] 
24.0 
[2.00] 76.5 
Avg. 
Dose
72.9
[2.08]
52.1
[2.08]
21.3
[2.13] 73.4 
52.1 
[2.08] 
26.6 
[2.22] 78.7 
Removed 
Tumor 
Points 
Max. 
Dose - - - - - 
27.2 
[2.26] 80.5 
Min. 
Dose - - - - - 
6.4 
[0.53] 57.8 
Avg. 
Dose - - - - - 
16.1 
[1.34] 68.2 
PTV2 
Max. 
Dose
75.0
[2.14]
53.6
[2.14]
23.4
[2.34] 75.3 
53.6 
[2.14] 
29.8 
[2.48] 80.5 
Min. 
Dose
70.0
[2.00]
50.0
[2.00]
9.0
[0.9] 59.1 
50.0 
[2.00] 
6.4 
[0.53] 56.6 
Avg. 
Dose
72.7
[2.08]
51.9
[2.08]
21.0
[2.10] 72.9 
51.9 
[2.08] 
22.5 
[1.87] 74.4 
Right  
Lung 
Max. 
Dose
73.2
[2.09]
52.3
[2.09]
21.0
[2.10] 73.3 
52.3 
[2.09] 
24.2 
[2.02] 75.6 
Avg. 
Dose
25.0
[0.71]
17.9
[0.71]
7.1
[0.71] 25.0 
17.9 
[0.71] 
7.1 
[0.60] 25.0 
Left  
Lung 
Max. 
Dose
62.8
[1.79]
44.8
[1.79]
16.1
[1.61] 58.3 
44.8 
[1.79] 
16.6 
[1.38] 55.7 
Avg. 
Dose
22.8
[0.65]
16.3
[0.65]
6.7
[0.67] 23.0 
16.3 
[0.65] 
7.1 
[0.59] 23.4 
Heart 
Max. 
Dose
70.2
[2.01]
50.2
[2.01]
18.9
[1.89] 69.1 
50.2 
[2.01] 
25.2 
[2.10] 75.2 
Avg. 
Dose
24.2
[0.69]
17.3
[0.69]
7.1
[0.71] 24.4 
17.3 
[0.69] 
7.3 
[0.61] 24.6 
Esophagus 
Max. 
Dose
60.6
[1.73]
43.3
[1.73]
17.2
[1.72] 60.4 
43.3 
[1.73] 
20.4 
[1.70] 61.1 
Avg. 
Dose
27.6
[0.79]
19.7
[0.79]
7.7
[0.77] 27.4 
19.7 
[0.79] 
8.9 
[0.74] 28.6 
Not 
Otherwise 
Specified 
Max. 
Dose
73.5
[2.10]
52.5
[2.10]
21.0
[2.10] 73.5 
52.5 
[2.10] 
25.2 
[2.10] 77.7 
Avg. 
Dose
24.6
[0.70]
17.5
[0.70]
7.1
[0.71] 24.6 
17.5 
[0.70] 
7.6 
[0.63] 25.2 
Spinal Cord 
Max. 
Dose
45.0
[1.29]
32.1
[1.29]
15.5
[1.55] 45.0 
32.1 
[1.29] 
17.7 
[1.48] 45.0 
Avg. 
Dose
23.9
[0.68]
17.1
[0.68]
6.92
[0.69] 24.0 
17.1 
[0.68] 
7.77 
[0.65] 24.9 
# of Fractions Given 35 25 10 35 25 12 37
                                                            
3 The fraction size doses are given in brackets below the cumulative doses. PTV2 represents the 
secondary target. 
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Appendix B4: No Adaptation vs. Two-Epoch Adaptation Results for the Lung1 Test 
Case (The ratio model solved in the optimization and the optimized doses rescaled if necessary)   
Structure 
Dose 
Statistics 
(Gy) 
No 
Adaptation 
(No Boost)
No Adaptation (with 
Boost) Two-Epoch Adaptation 
Total Main Stage 
Boost 
Stage Total 
Epoch 
1 
Epoch 
2 (with 
Boost) 
Total 
Tumor 
Max. 
Dose 
73.6
[2.17]
54.1
[2.17]
22.1
[2.21] 75.3 
54.1 
[2.17] 
28.9 
[2.41] 80.4 
Min.  
Dose 
69.9
[2.06]
51.4
[2.06]
20.0
[2.00] 71.5 
51.4 
[2.06] 
24.0 
[2.00] 76.4 
Avg.  
Dose 
71.6
[2.11]
52.7
[2.11]
20.7
[2.07] 73.4 
52.7 
[2.11] 
25.6 
[2.13] 78.3 
Removed 
Tumor 
Points 
Max. 
Dose - - - - - 
26.7 
[2.22] 80.4 
Min.  
Dose - - - - - 
6.0 
[0.50] 57.7 
Avg.  
Dose - - - - - 
14.8 
[1.24] 67.5 
PTV2 
Max. 
Dose 
73.6
[2.17]
54.1
[2.17]
22.2
[2.22] 75.3 
54.1 
[2.17] 
28.9 
[2.41] 80.4 
Min.  
Dose 
68.0
[2.00]
50
[2.00]
9.7
[0.97] 59.7 
50.0 
[2.00] 
6.0 
[0.50] 56.0 
Avg.  
Dose 
71.3
[2.10]
52.4
[2.10]
20.4
[2.04] 72.9 
52.4 
[2.10] 
21.6 
[1.80] 74.0 
Right  
Lung 
Max. 
Dose 
71.4
[2.10]
52.5
[2.10]
21.0
[2.10] 73.5 
52.5 
[2.10] 
23.2 
[1.93] 75.1 
Avg.  
Dose 
24.5
[0.72]
18.0
[0.72]
6.9
[0.69] 25.0 
18.0 
[0.72] 
6.7 
[0.56] 24.7 
Left  
Lung 
Max. 
Dose 
55.0
[1.62]
40.4
[1.62]
15.3
[1.53] 55.7 
40.4 
[1.62] 
14.8 
[1.24] 52.8 
Avg.  
Dose 
22.5
[0.66]
16.5
[0.66]
6.5
[0.65] 23.0 
16.5 
[0.66] 
6.5 
[0.54] 23.0 
Heart 
Max. 
Dose 
69.5
[2.04]
51.1
[2.04]
19.7
[1.97] 70.6 
51.1 
[2.04] 
25.2 
[2.10] 76.1 
Avg.  
Dose 
23.7
[0.70]
17.5
[0.70]
7.0
[0.70] 24.4 
17.5 
[0.70] 
7.0 
[0.58] 24.4 
Esophagus 
Max. 
Dose 
58.3
[1.72]
42.9
[1.72]
16.1
[1.61] 58.9 
42.9 
[1.72] 
19.0 
[1.58] 60.0 
Avg.  
Dose 
27.3
[0.8]
20.1
[0.80]
7.5
[0.75] 27.6 
20.1 
[0.80] 
7.8 
[0.65] 27.8 
Not 
Otherwise 
Specified 
Max. 
Dose 
71.4
[2.10]
52.5
[2.10]
21.0
[2.10] 73.5 
52.5 
[2.10] 
25.2 
[2.10] 77.7 
Avg.  
Dose 
24.2
[0.71]
17.8
[0.71]
6.9
[0.69] 24.7 
17.8 
[0.71] 
7.2 
[0.60] 25.0 
Spinal Cord 
Max. 
Dose 
44.1
[1.30]
32.4
[1.30]
15.3
[1.53] 44.9 
32.4 
[1.30] 
15.0 
[1.25] 44.5 
Avg.  
Dose 
23.4
[0.69]
17.2
[0.69]
6.8
[0.68] 24.0 
17.2 
[0.69] 
7.0 
[0.59] 24.2 
# of Fractions Given 34 25 10 35 25 12 37
 
                                                            
4 The fraction size doses are given in brackets below the cumulative doses. PTV2 represents the 
secondary target. 
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Appendix C5: No Adaptation vs. Two-Epoch Adaptation Results for the CERRLung Test Case 
(The ratio model solved in the optimization and the optimized doses rescaled if necessary)  
Structure 
Dose 
Statistics 
(Gy) 
No 
Adaptation 
(No Boost)
No Adaptation (with 
Boost) Two-Epoch Adaptation 
Total Main Stage 
Boost 
Stage Total 
Epoch 
1 
Epoch 
2 (with 
Boost)
Total 
Tumor 
Max. 
Dose 
78.0
[2.17]
54.1 
[2.17]
34.4 
[2.29] 86.2 
54.1 
[2.17] 
38.7 
[2.28] 90.6 
Min. 
Dose 
74.1
[2.06]
51.4 
[2.06]
30 
[2.0] 81.9 
51.4 
[2.06] 
34  
[2.0] 86.0 
Avg. 
Dose 
75.9
[2.11]
52.7 
[2.11]
31.5 
[2.1] 84.2 
52.7 
[2.11] 
35.8 
[2.1] 88.5 
Removed 
Tumor 
Points 
Max. 
Dose - - - - - 
37.7 
[2.22] 90.6 
Min. 
Dose - - - - - 
10.5 
[0.62] 62.5 
Avg. 
Dose - - - - - 
31.7 
[1.87] 84.5 
PTV2 
Max. 
Dose 
78.0
[2.17]
54.1 
[2.17]
34.9 
[2.33] 86.2 
54.1 
[2.17] 
39.3 
[2.31] 90.6 
Min. 
Dose 
72.0
[2.0]
50
[2.0]
12.7 
[0.84] 62.7 
50 
[2.0] 
3.6 
[0.21] 53.6 
Avg. 
Dose 
75.1
[2.09]
52.1 
[2.09]
28.7 
[1.91] 80.9 
52.1 
[2.09] 
30.6 
[1.8] 82.7 
Right  
Lung 
Max. 
Dose 
75.6
[2.1]
52.5 
[2.1]
31.5 
[2.1] 84.0 
52.5 
[2.1] 
35.7 
[2.1] 88.2 
Avg. 
Dose 
16.9
[0.47]
11.7 
[0.47]
5 
[0.33] 16.7 
11.7 
[0.47] 
5.1  
[0.3] 16.9 
Left  
Lung 
Max. 
Dose 
75.6
[2.1]
52.5 
[2.1]
31.5 
[2.1] 82.5 
52.5 
[2.1] 
33.2 
[1.95] 82.0 
Avg. 
Dose 
9.7
[0.27]
6.7 
[0.27]
2.7 
[0.18] 9.5 
6.7 
[0.27] 
2.6 
[0.15] 9.3 
Heart 
Max. 
Dose 
72.7
[2.02]
50.5 
[2.02]
17.1 
[1.14] 67.6 
50.5 
[2.02] 
20.7 
[1.22] 68.2 
Avg. 
Dose 
4.2
[0.12]
2.9 
[0.12]
0.9 
[0.06] 3.9 
2.9 
[0.12] 
1  
[0.06] 4.0 
Esophagus 
Max. 
Dose 
75.6
[2.1]
52.5 
[2.1]
22.9 
[1.53] 75.3 
52.5 
[2.1] 
20.3 
[1.19] 72.7 
Avg. 
Dose 
16.6
[0.46]
11.5 
[0.46]
3.2 
[0.21] 14.7 
11.5 
[0.46] 
3  
[0.17] 14.5 
Not 
Otherwise 
Specified 
Max. 
Dose 
75.6
[2.1]
52.5 
[2.1]
31.5 
[2.1] 84.0 
52.5 
[2.1] 
35.7 
[2.1] 88.2 
Avg. 
Dose 
7.5 
[0.21]
5.2 
[0.21]
2.3 
[0.15] 7.5 
5.2 
[0.21] 
2.4 
[0.14] 7.6 
Spinal Cord 
Max. 
Dose 
10.4
[0.29]
7.2 
[0.29]
6.8 
[0.45] 10.4 
7.2 
[0.29] 
7.7 
[0.45] 11.3 
Avg. 
Dose 
1.6
[0.04]
1.1 
[0.04]
0.6 
[0.04] 1.7 
1.1 
[0.04] 
0.5 
[0.03] 1.6 
# of Fractions Given 36 25 15 40 25 17 42
 
                                                            
5 The fraction size doses are given in brackets below the cumulative doses. PTV2 represents the 
secondary target. 
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Appendix D6: Three-Epoch Adaptation Results for the Lung1 Case (Adapted after fraction 10 
and 25, the uniform fractionation model solved in the re-optimization) 
Structure 
Dose 
Statistics 
(Gy) 
Same 
plan is 
delivered 
for the 
first 
epoch 
The original tumor 
shrinks 20% towards the 
residual tumor after 
fraction 25 during the 
first 10 fractions 
The original tumor 
shrinks 50% towards the 
residual tumor after 
fraction 25 during the 
first 10 fractions 
The original tumor 
shrinks 80% towards the 
residual tumor after 
fraction 25 during the 
first 10 fractions 
Epoch 
1 
Epoch 
2 
Epoch 
3 (with 
Boost) 
Total Epoch 2 
Epoch 
3 
(with 
Boost)
Total Epoch 2 
Epoch
3 
(with 
Boost)
Total 
Tumor 
Max. 
Dose 
21.4 
[2.14] 
32.3
[2.15]
29.6
[2.47] 80.6 
32.8
[2.19]
29.5
[2.46] 81.0 
33.5 
[2.23] 
29.4
[2.45] 81.2 
Min. 
Dose 
20.4 
[2.04] 
30.5
[2.03]
24.0
[2.00] 76.5 
30.6
[2.04]
24
[2] 76.9 
31 
[2.06] 
24.0
[2.00] 77.1 
Avg. 
Dose 
20.8 
[2.08] 
31.4
[2.09]
26.6
[2.22] 78.8 
31.7
[2.11]
26.6
[2.22] 79.2 
32 
[2.13] 
26.5
[2.21] 79.3 
Removed 
Tumor 
Points 
Max. 
Dose - 
32.2
[2.15]
27.1
[2.26] 80.6 
32.7
[2.18]
27.2
[2.27] 81.0 
33.4 
[2.22] 
27.3
[2.28] 81.2 
Min. 
Dose - 
30.0
[2.00]
6.5
[0.55] 57.2 
30.0
[2.00]
6.5
[0.54] 57.2 
30.0 
[2.00] 
6.5
[0.55] 57.2 
Avg. 
Dose - 
31.0
[2.07]
16.2
[1.35] 68.3 
31.2
[2.08]
16.2
[1.35] 68.5 
31.2 
[2.08] 
16.2
[1.35] 68.4 
PTV2 
Max. 
Dose 
21.4 
[2.14 
32.3
[2.15]
29.9
[2.49] 80.6 
32.9
[2.19]
29.7
[2.47] 81.0 
33.2 
[2.22] 
29.6
[2.47] 81.2 
Min. 
Dose 
20.0 
[2.00] 
30.0
[2.00]
6.5
[0.54] 56.6 
30.0
[2.00]
6.4
[0.54] 56.5 
30.0 
[2.00] 
6.5
[0.54] 56.6 
Avg. 
Dose 
20.8 
[2.08] 
31.2
[2.08]
22.5
[1.88] 74.5 
31.5
[2.1]
22.6
[1.88] 74.8 
31.6 
[2.11] 
22.5
[1.87] 74.8 
Right Lung 
Max. 
Dose 
20.9 
[2.09] 
31.4 
[2.10] 
24.2 
[2.02] 
75.5 
 
31.3 
[2.08] 
24.7 
[2.06] 76.0 
31.4 
[2.1] 
24.6 
[2.05] 76.3 
Avg. 
Dose 
7.1 
[0.71] 
10.7
[0.71]
7.1
[0.6] 25.0 
10.7
[0.71]
7.1
[0.6] 25.0 
10.7 
[0.71] 
7.1
[0.6] 25.0 
Left 
Lung 
Max. 
Dose 
17.9 
[1.79] 
25.9
[1.73]
16.7
[1.39] 54.1 
24.7
[1.64]
16.2
[1.35] 52.3 
23.4 
[1.56] 
16.4
[1.36] 51.9 
Avg. 
Dose 
6.5 
[0.65] 
9.8 
[0.65]
7.2
[0.6] 23.5 
9.8
[0.66]
7.1
[0.59] 23.5 
9.8 
[0.65] 
7.1
[0.59] 23.4 
Heart 
Max. 
Dose 
20.1 
[2.01] 
30.4
[2.03]
25.2
[2.1] 75.5 
31.2
[2.08]
25.2
[2.1] 76.4 
31.4 
[2.09] 
25.2
[2.1] 76.6 
Avg. 
Dose 
6.9 
[0.69] 
10.4
[0.69]
7.3
[0.61] 24.6 
10.4
[0.69]
7.3
[0.61] 24.7 
10.4 
[0.69] 
7.3
[0.61] 24.6 
Esoph. 
Max. 
Dose 
17.3 
[1.73] 
25.8
[1.72]
20.5
[1.71] 61.2 
25.6
[1.71]
20.6
[1.72] 61.6 
27.3 
[1.82] 
20.4
[1.7] 61.4 
Avg. 
Dose 
7.9 
[0.79] 
11.9
[0.79]
9
[0.75] 28.7 
12.1
[0.81]
8.9
[0.74] 28.9 
12.2 
[0.82] 
9.0
[0.75] 29.1 
N.O.S. 
Max. 
Dose 
21.0 
[2.10] 
31.5
[2.10]
25.2
[2.1] 77.7 
31.5
[2.1]
25.2
[2.1] 77.7 
31.5 
[2.1] 
25.2
[2.1] 77.7 
Avg. 
Dose 
7.0 
[0.70] 
10.5
[0.70]
7.6
[0.64] 25.2 
10.6
[0.71]
7.6
[0.63] 25.2 
10.6 
[0.71] 
7.6
[0.63] 25.2 
Spinal 
Cord 
Max. 
Dose 
12.9 
[1.29] 
19.3
[1.29]
18.1
[1.51] 45.0 
19.3
[1.29]
17.4
[1.45] 45.0 
19.3 
[1.29] 
16.7
[1.39] 45.0 
Avg. 
Dose 
6.8 
[0.68] 
10.3
[0.68]
7.8
[0.65]
24.9 10.3
[0.68]
7.7
[0.64]
24.8 10.2 
[0.68] 
7.6
[0.64] 24.7 
# of Fractions Given 10 15 12 37 15 12 37 15 12 37
 
                                                            
6 The fraction size doses are given in brackets below the cumulative doses. PTV2 represents the 
secondary target. “N.O.S” is abbreviation of “Not Otherwise Specified” tissue. 
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Appendix E7: Three-Epoch Adaptation Results for the CERRLung Case (Adapted after fraction 
10 and 25, the uniform fractionation model solved in the re-optimization) 
Structure 
Dose 
Statistics 
(Gy) 
Same 
plan is 
delivered 
for the 
first 
epoch 
The original tumor 
shrinks 20% towards the 
residual tumor after 
fraction 25 during the 
first 10 fractions 
The original tumor 
shrinks 50% towards the 
residual tumor after 
fraction 25 during the 
first 10 fractions 
The original tumor 
shrinks 80% towards 
the residual tumor after 
fraction 25 during the 
first 10 fractions 
Epoch 
1 
Epoch 
2 
Epoch 
3 (with 
Boost) 
Total Epoch 2 
Epoch 
3 
(with 
Boost)
Total Epoch 2 
Epoch
3 
(with 
Boost)
Total
Tumor 
Max. 
Dose 
21.7 
[2.17] 
32.7
[2.18]
39.0
[2.3] 91.0 
32.9
[2.19]
39.1
[2.3] 91.0 
32.9 
[2.19] 
39.0
[2.29] 91.0 
Min. 
Dose 
20.6 
[2.06] 
30.8
[2.05]
34.0
[2.00] 86.5 
30.9
[2.06]
34.0
[2.00] 86.5 
31.0 
[2.06] 
34.0
[2.00] 86.5 
Avg. 
Dose 
21.2 
[2.12] 
31.8
[2.12]
36.0
[2.12] 88.9 
31.9
[2.12]
35.9
[2.11] 89.0 
31.9 
[2.13] 
35.9
[2.11] 89.0 
Removed 
Tumor 
Voxels 
Max. 
Dose - 
32.6
[2.17]
37.7
[2.22] 91.0 
32.7
[2.18]
37.4
[2.2] 91.0 
32.7 
[2.18] 
30.9
[1.82] 91.0 
Min. 
Dose - 
30.0
[2.00]
10.8
[0.64] 63.5 
30.0
[2.00]
11.0
[0.65] 63.5 
30.0 
[2.00] 
37.5
[2.21] 64.0 
Avg. 
Dose - 
31.3
[2.08]
31.9
[1.88] 84.8 
31.3
[2.09]
32.1
[1.89] 84.8 
31.3 
[2.09] 
11.0
[0.65] 84.7 
PTV2 
Max. 
Dose 
21.7 
[2.17] 
32.8
[2.19]
39.6
[2.33] 91.0 
33.0
[2.20]
40.6
[2.39] 91.0 
33.1 
[2.21] 
40.0
[2.35] 91.0 
Min. 
Dose 
20.0 
[2.00] 
30.0
[2.00]
4.3
[0.25] 54.3 30[2] 
3.9
[0.23] 53.9 
30.0 
[2.00] 
4.1
[0.24] 54.1 
Avg. 
Dose 
20.9 
[2.09] 
31.4
[2.09]
30.8
[1.81] 83.1 
31.4
[2.09]
30.9
[1.82] 83.2 
31.4 
[2.09] 
30.9
[1.82] 83.2 
Right 
Lung 
Max. 
Dose 
21.0 
[2.10] 
31.5 
[2.10] 
35.7 
[2.10] 88.2 
31.5 
[2.10] 
35.7 
[2.10] 88.2 
31.5 
[2.10] 
35.7 
[2.10] 84.7 
Avg. 
Dose 
4.7 
[0.47] 
7.1 
[0.47]
5.2
[0.31] 17.0 
7.1
[0.47]
5.2
[0.31] 17.0 
7.1 
[0.47] 
5.2
[0.31] 17.0 
Left 
Lung 
Max. 
Dose 
21.0 
[2.10] 
31.5
[2.1]
32.3
[1.9] 81.6 
31.5
[2.1]
32.5
[1.91] 81.8 
31.5 
[2.10] 
33.5
[1.97] 82.2 
Avg. 
Dose 
2.7 
[0.27] 
4.0 
[0.27]
2.6
[0.15] 9.3 
3.9
[0.26]
2.6
[0.15] 9.2 
4.0 
[0.27] 
2.6
[0.15] 9.3 
Heart 
Max. 
Dose 
20.1 
[2.01] 
30.7
[2.04]
20.8
[1.23] 70.8 
31.1
[2.07]
21.2
[1.25] 71.3 
31.3 
[2.09] 
21.9
[1.29] 72.3 
Avg. 
Dose 
1.2 
[0.12] 
1.8 
[0.12]
1.0
[0.06] 4.0 
1.8
[0.12]
1.0
[0.06] 4.0 
1.8 
[0.12] 
1.1
[0.06] 4.0 
Esoph. 
Max. 
Dose 
21.0 
[2.1] 
31.5
[2.1]
22.4
[1.32] 74.8 
31.5
[2.1]
20
[1.18] 72.4 
31.5 
[2.1] 
21.6
[1.27] 74.0 
Avg. 
Dose 
4.7 
[0.47] 
7.0 
[0.47]
3.1
[0.18] 14.8 
7.1
[0.47]
2.8
[0.17] 14.6 
7.2 
[0.48] 
3
[0.18] 14.8 
N.O.S. 
Max. 
Dose 
21.0 
[2.10] 
31.5
[2.1]
35.7
[2.1] 88.2 
31.5
[2.1]
35.7
[2.1] 88.2 
31.5 
[2.10] 
35.7
[2.10] 88.2 
Avg. 
Dose 
2.1 
[0.21] 
3.1 
[0.21]
2.4
[0.14] 7.6 
3.1
[0.21]
2.4
[0.14] 7.6 
3.1 
[0.21] 
2.4
[0.14] 7.6 
Spinal 
Cord 
Max. 
Dose 
2.6 
[0.26] 
5.4 
[0.36]
7.0
[0.41] 12.1 
5.3
[0.35]
7.4
[0.43] 13.8 
4.8 
[0.32] 
8.4
[0.49] 13.2 
Avg. 
Dose 
0.5 
[0.05] 
0.8 
[0.05]
0.5
[0.03] 1.8 
0.9
[0.06]
0.5
[0.03] 1.9 
0.8 
[0.05] 
0.5
[0.03] 1.8 
# of Fractions Given 10 15 17 42 15 17 42 15 17 42
                                                            
7 The fraction size doses are given in brackets below the cumulative doses. PTV2 represents the 
secondary target. “N.O.S” is abbreviation of “Not Otherwise Specified” tissue. 
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Appendix F8: Three-Epoch Adaptation Results for the Lung1 Case (Adapted after fraction 25 
and 30, the uniform fractionation model solved in the re-optimization) 
Structure 
Dose 
Statistics 
(Gy) 
Same plan is 
delivered for the 
first two epochs 
The residual 
tumor after 
fraction 25 
shrinks 10%
The residual 
tumor after 
fraction 25 
shrinks 30% 
The residual 
tumor after 
fraction 25 
shrinks 50%
Epoch 
1 
Epoch 
2 (with 
Boost)
Epoch 
3 (with 
Boost)
Total 
Epoch 
3 (with 
Boost)
Total 
Epoch 
3 (with 
Boost)
Total 
Tumor 
Max. 
Dose 
53.6 
[2.14] 
12.3
[2.47]
19.5
[2.43] 82.3 
19.7
[2.46] 82.8 
23.5
[2.35] 86.7 
Min. 
Dose 
50.9 
[2.04] 
10.0
[2.00]
16.0
[2.00] 78.2 
16.0
[2.00] 78.6 
20.0
[2.00] 82.4 
Avg. 
Dose 
52.1 
[2.08] 
11.1
[2.22]
17.0
[2.12] 80.2 
17.7
[2.22] 80.9 
21.1
[2.11] 84.2 
Removed 
Tumor 
Points 
Max. 
Dose - 
11.3
[2.26]
17.5
[2.19] 81.9 
18.3
[2.29] 82.8 
22.0
[2.20] 86.4 
Min. 
Dose - 
2.7
[0.53]
3.8
[0.47] 57.8 
3.6
[0.45] 57.6 
3.7 
[0.37] 57.6 
Avg. 
Dose - 
6.7
[1.34]
9.0
[1.12] 68.3 
9.5
[1.18] 69.8 
9.1 
[0.91] 70.0 
PTV2 
Max. 
Dose 
53.6 
[2.14] 
12.4
[2.48]
19.5
[2.44] 82.3 
19.9
[2.49] 82.8 
23.5
[2.35] 86.7 
Min. 
Dose 
50.0 
[2.00] 
2.6
[0.53]
3.8
[0.48] 56.5 
3.6
[0.45] 57.3 
3.7 
[0.37] 57.2 
Avg. 
Dose 
51.9 
[2.08] 
9.4
[1.87]
13.6
[1.7] 74.9 
13.2
[1.65] 74.5 
13.2
[1.32] 74.5 
Right 
Lung 
Max. 
Dose 
52.3 
[2.09] 
10.1
[2.02]
14.8
[1.86] 76.3 
15.5
[1.94] 77.0 
16.1
[1.61] 72.1 
Avg. 
Dose 
17.9 
[0.71] 
3.0
[0.6]
4.2
[0.52] 25.0 
4.2
[0.52] 25.0 
4.2 
[0.42] 25.0 
Left  
Lung 
Max. 
Dose 
44.8 
[1.79] 
6.9
[1.38]
10.5
[1.31] 57.1 
11.8
[1.47] 56.6 
13.3
[1.33] 55.7 
Avg. 
Dose 
16.3 
[0.65] 
3.0
[0.59]
4.1
[0.51] 23.4 
4.4
[0.55] 23.7 
4.2 
[0.42] 23.5 
Heart 
Max. 
Dose 
50.2 
[2.01] 
10.5
[2.1]
15.8
[1.97] 76.3 
16.8
[2.1] 77.3 
18.7
[1.87] 79.3 
Avg. 
Dose 
17.3 
[0.69] 
3.0
[0.61]
4.3
[0.53] 24.6 
4.4
[0.55] 24.7 
4.5 
[0.45] 24.9 
Esoph. 
Max. 
Dose 
43.3 
[1.73] 
8.5
[1.7]
13.1
[1.63] 62.2 
15
[1.87] 64.2 
16.9
[1.69] 66.0 
Avg. 
Dose 
19.7 
[0.79] 
3.7
[0.74]
4.9
[0.61] 28.3 
5.7
[0.72] 29.2 
5.4 
[0.54] 28.9 
N.O.S. 
Max. 
Dose 
52.5 
[2.10] 
10.5
[2.1]
16.8
[2.1] 79.8 
16.8
[2.1] 79.8 
21.0
[2.10] 84.0 
Avg. 
Dose 
17.5 
[0.70] 
3.2
[0.63]
4.6
[0.58] 25.3 
4.7
[0.58] 25.4 
4.8 
[0.48] 25.5 
Spinal 
Cord 
Max. 
Dose 
32.1 
[1.29] 
7.4
[1.48]
9.7
[1.21] 45.0 
16.5
[2.06] 45.0 
12.6
[1.26] 45.0 
Avg. 
Dose 
17.1 
[0.68] 
3.2
[0.65]
4.6
[0.57] 24.9 
5
[0.63] 25.4 
4.8 
[0.48] 25.1 
# of Fractions Given 25 5 8 38 8 38 10 40
 
                                                            
8 The fraction size doses are given in brackets below the cumulative doses. PTV2 represents the 
secondary target. “N.O.S” is abbreviation of “Not Otherwise Specified” tissue. 
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Appendix G9: Three-Epoch Adaptation Results for the CERRLung Case (Adapted after fraction 
25 and 30, the uniform fractionation model solved in the re-optimization) 
Structure 
Dose 
Statistics 
(Gy) 
Same plan is 
delivered for the 
first two epochs 
The residual 
tumor after 
fraction 25 
shrinks 10%
The residual 
tumor after 
fraction 25 
shrinks 30% 
The residual 
tumor after 
fraction 25 
shrinks 50%
Epoch 
1 
Epoch 
2 (with 
Boost)
Epoch 
3 (with 
Boost)
Total 
Epoch 
3 (with 
Boost)
Total 
Epoch 
3 (with 
Boost)
Total 
Tumor 
Max. 
Dose 
54.3 
[2.17] 
11.5 
[2.3]
28.0 
[2.33] 91.4 
30.2 
[2.32] 93.4 
32.9 
[2.35] 95.9 
Min. 
Dose 
51.6 
[2.06] 10 [2] 
24.0
[2] 86.8 26 [2] 88.8 
28.0 
[2.0] 91.1 
Avg. 
Dose 
52.9 
[2.12] 
10.6 
[2.12]
25.8 
[2.15] 89.3 
27.7 
[2.13] 91.1 
30.2 
[2.16] 93.6 
Removed 
Tumor 
Points 
Max. 
Dose - 
11.1 
[2.22]
27.7 
[2.31] 91.4 
30.1 
[2.31] 93.4 
32.4 
[2.31] 95.9 
Min. 
Dose - 
3.3 
[0.65]
4.2
[0.35] 60.6 
3.4
[0.26] 60.6 
2.4 
[0.17] 59.8 
Avg. 
Dose - 
9.4 
[1.88]
21.6
[1.8] 84.0 
21.9 
[1.69] 84.6 
22.7 
[1.62] 85.6 
PTV2 
Max. 
Dose 
54.3 
[2.17] 
11.8 
[2.35]
29.0 
[2.42] 91.4 
30.1 
[2.32] 93.4 
33.3 
[2.38] 95.9 
Min. 
Dose 
50 
[2.0] 
1.2 
[0.25]
2.0
[0.16] 53.2 
2.1
[0.16] 53.3 
1.5 
[0.1] 53.0 
Avg. 
Dose 
52.3 
[2.09] 
9.1 
[1.81]
21.6
[1.8] 82.9 
21.8 
[1.68] 83.2 
22.5 
[1.61] 83.8 
Right 
Lung 
Max. 
Dose 
52.5 
[2.1] 
10.5 
[2.1]
25.2
[2.1] 88.2 
27.3
[2.1] 90.3 
29.4 
[2.1] 92.4 
Avg. 
Dose 
11.8 
[0.47] 
1.5 
[0.31]
3.7
[0.31] 17.0 
3.7
[0.28] 17.0 
3.7 
[0.26] 17.0 
Left  
Lung 
Max. 
Dose 
52.5 
[2.1] 
9.5
[1.9]
24.8 
[2.06] 83.5 
23.6 
[1.82] 73.5 
29.3 
[2.09] 84.3 
Avg. 
Dose 
6.7 
[0.27] 
0.8 
[0.16]
1.8
[0.15] 9.3 
1.6
[0.12] 9.1 
1.8 
[0.13] 9.3 
Heart 
Max. 
Dose 
50.2 
[2.01] 
6.1 
[1.21]
15.7 
[1.31] 69.3 
15.4 
[1.18] 65.4 
16.7 
[1.2] 61.6 
Avg. 
Dose 
2.9 
[0.12] 
0.3 
[0.06]
0.7
[0.06] 4.0 
0.6
[0.05] 3.9 
0.6 
[0.04] 3.9 
Esoph. 
Max. 
Dose 
52.5 
[2.1] 
6.5 
[1.29]
15.3 
[1.28] 74.3 
13.0
[1.0] 71.7 
9.6 
[0.69] 68.4 
Avg. 
Dose 
11.7 
[0.47] 
0.9 
[0.18]
1.9
[0.15] 14.4 
1.7
[0.13] 14.3 
1.4 
[0.1] 14.0 
N.O.S. 
Max. 
Dose 
52.5 
[2.1] 
10.5 
[2.1]
25.2
[2.1] 88.2 
27.3
[2.1] 90.3 
29.4 
[2.1] 92.4 
Avg. 
Dose 
5.2 
[0.21] 
0.7 
[0.14]
1.6
[0.14] 7.6 
1.6
[0.13] 7.6 
1.7 
[0.12] 7.6 
Spinal 
Cord 
Max. 
Dose 
6.6 
[0.26] 
2.1 
[0.42]
1.4
[0.12] 7.6 
2.6
[0.2] 9.2 
4.4 
[0.31] 10.4 
Avg. 
Dose 
1.2 
[0.05] 
0.2 
[0.03]
0.3
[0.02] 1.6 
0.5
[0.04] 1.8 
0.5 
[0.04] 1.8 
# of Fractions Given 25 5 12 42 13 43 14 44
                                                            
9 The fraction size doses are given in brackets below the cumulative doses. PTV2 represents the 
secondary target. “N.O.S.” is abbreviation of “Not Otherwise Specified” tissue. 
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Appendix H10: Three-Epoch Adaptation Results for the Lung1 Case (Adapted after fraction 25 
and 30, the ratio model is solved in the re-optimization and the re-optimized doses rescaled if 
necessary) 
Structure 
Dose 
Statistics 
(Gy) 
Same plan is 
delivered for the 
first two epochs 
The residual 
tumor after 
fraction 25 
shrinks 10%
The residual 
tumor after 
fraction 25 
shrinks 30% 
The residual 
tumor after 
fraction 25 
shrinks 50%
Epoch 
1 
Epoch 
2 (with 
Boost)
Epoch 
3 (with 
Boost)
Total 
Epoch 
3 (with 
Boost)
Total 
Epoch 
3 (with 
Boost)
Total 
Tumor 
Max. 
Dose 
54.1 
[2.17] 
12.1
[2.41]
19.0
[2.38] 82.5 
18.7
[2.34] 82.7 
21.9
[2.43] 85.0 
Min. 
Dose 
51.4 
[2.06] 
10.0
[2.00]
16.0
[2.00] 78.4 
16.0
[2.00] 78.5 
18 
[2] 80.7 
Avg. 
Dose 
52.7 
[2.11] 
10.7
[2.13]
16.9
[2.12] 80.3 
17.0
[2.13] 80.3 
19.3
[2.14] 82.6 
Removed 
Tumor 
Points 
Max. 
Dose - 
11.1
[2.22]
17.4
[2.18] 82.2 
17.8
[2.22] 82.7 
20 
[2.22] 84.1 
Min. 
Dose - 
2.5
[0.50]
3.8
[0.47] 58.4 
3.4
[0.42] 57.5 
3.3 
[0.37] 57.5 
Avg. 
Dose - 
6.2
[1.24]
8.9
[1.11] 68.4 
8.4
[1.05] 68.8 
8.3 
[0.92] 69.2 
PTV2 
Max. 
Dose 
54.1 
[2.17] 
12.1
[2.41]
19.0
[2.38] 82.5 
18.8
[2.35] 82.7 
21.3
[2.37] 85.0 
Min. 
Dose 
50.0 
[2.00] 
2.5
[0.5]
3.8
[0.47] 56.3 
3.4
[0.42] 56.2 
3.3 
[0.37] 57.1 
Avg. 
Dose 
52.4 
[2.1] 
9.0
[1.80]
13.6
[1.7] 75.0 
12.4
[1.55] 73.8 
12.0
[1.33] 73.4 
Right 
Lung 
Max. 
Dose 
52.5 
[2.1] 
9.7
[1.93]
15.2
[1.89] 76.7 
14.6
[1.83] 76.2 
14.3
[1.59] 70.4 
Avg. 
Dose 
18.0 
[0.72] 
2.8
[0.56]
4.2
[0.52] 25.0 
3.8
[0.47] 24.6 
3.8 
[0.42] 24.6 
Left 
 Lung 
Max. 
Dose 
40.4 
[1.62] 
6.2
[1.24]
9.8
[1.22] 53.1 
13.1
[1.64] 52.1 
10.7
[1.19] 50.0 
Avg. 
Dose 
16.5 
[0.66] 
2.7
[0.54]
4.1
[0.51] 23.3 
3.8
[0.47] 23.0 
3.9 
[0.43] 23.1 
Heart 
Max. 
Dose 
51.1 
[2.04] 
10.5
[2.1]
14.5
[1.81] 75.9 
16.8
[2.1] 78.2 
17.2
[1.91] 78.4 
Avg. 
Dose 
17.5 
[0.7] 
2.9
[0.58]
4.2
[0.53] 24.6 
4.0
[0.51] 24.4 
4.2 
[0.47] 24.6 
Esoph. 
Max. 
Dose 
42.9 
[1.72] 
7.9
[1.58]
13.1
[1.63] 62.0 
13.1
[1.63] 62.0 
14.9
[1.65] 63.8 
Avg. 
Dose 
20.1 
[0.8] 
3.2
[0.65]
4.9
[0.61] 28.2 
4.7
[0.59] 28.1 
5.0 
[0.56] 28.3 
N.O.S. 
Max. 
Dose 
52.5 
[2.1] 
10.5
[2.1]
16.8
[2.1] 79.8 
16.8
[2.1] 79.8 
18.9
[2.1] 81.9 
Avg. 
Dose 
17.8 
[0.71] 
3.0
[0.6]
4.6
[0.57] 25.4 
4.3
[0.54] 25.1 
4.4 
[0.48] 25.1 
Spinal 
Cord 
Max. 
Dose 
32.4 
[1.3] 
6.3
[1.25]
9.2
[1.15] 45.0 
9.3
[1.16] 44.3 
13.1
[1.45] 44.3 
Avg. 
Dose 
17.2 
[0.69] 
2.9
[0.59]
4.5
[0.57] 24.7 
4.2
[0.53] 24.4 
4.4 
[0.49] 24.6 
# of Fractions Given 25 5 8 38 8 38 9 39
                                                            
10 The fraction size doses are given in brackets below the cumulative doses. PTV2 represents the 
secondary target. “N.O.S.” is abbreviation of “Not Otherwise Specified” tissue. 
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Appendix I11: Three-Epoch Adaptation Results for the CERRLung Case (Adapted after fraction 
25 and 30, the ratio model solved in the re-optimization and the re-optimized doses rescaled if 
necessary) 
Structure 
Dose 
Statistics 
(Gy) 
Same plan is 
delivered for the 
first two epochs 
The residual 
tumor after 
fraction 25 
shrinks 10%
The residual 
tumor after 
fraction 25 
shrinks 30% 
The residual 
tumor after 
fraction 25 
shrinks 50%
Epoch 
1 
Epoch 
2 (with 
Boost)
Epoch 
3 (with 
Boost)
Total 
Epoch 
3 (with 
Boost)
Total 
Epoch 
3 (with 
Boost)
Total 
Tumor 
Max. 
Dose 
54.1 
[2.17] 
11.4 
[2.28]
27.5 
[2.29] 90.6 
29.7 
[2.28] 92.9 
34.4 
[2.3] 97.5 
Min. 
Dose 
51.4 
[2.06] 
10
[2.0]
24.0
[2.0] 86.1 
26.0
[2.0] 88.3 
30.0
[2.0] 92.6 
Avg. 
Dose 
52.7 
[2.11] 
10.5 
[2.1]
25.3 
[2.11] 88.5 
27.5 
[2.11] 90.6 
31.8 
[2.12] 94.9 
Removed 
Tumor 
Points 
Max. 
Dose - 
11.1 
[2.22]
27.0 
[2.25] 90.6 
29.7 
[2.28] 92.9 
33.9 
[2.26] 97.5 
Min. 
Dose - 
3.1 
[0.62]
4.0
[0.34] 59.8 
3.6
[0.28] 59.9 
2.0 
[0.13] 58.9 
Avg. 
Dose - 
9.3 
[1.87]
21.4 
[1.78] 83.6 
22.1
[1.7] 84.5 
23.6 
[1.58] 86.2 
PTV2 
Max. 
Dose 
54.1 
[2.17] 
11.6 
[2.31]
27.8 
[2.31] 90.6 
29.6 
[2.28] 92.9 
35.8 
[2.39] 97.5 
Min. 
Dose 
50 
[2.0] 
1.1 
[0.21]
2.0
[0.17] 53.1 
2.0
[0.15] 53.1 
1.5
[0.1] 52.7 
Avg. 
Dose 
52.1 
[2.09] 
9.0
[1.8]
21.1 
[1.76] 82.2 
21.8 
[1.68] 83.0 
23.5 
[1.57] 84.7 
Right 
Lung 
Max. 
Dose 
52.5 
[2.1] 
10.5 
[2.1]
25.2
[2.1] 88.2 
27.3
[2.1] 90.3 
31.5
[2.1] 94.5 
Avg. 
Dose 
11.7 
[0.47] 
1.5 
[0.3]
3.5
[0.29] 16.7 
3.6
[0.28] 16.9 
3.7 
[0.25] 17.0 
Left 
Lung 
Max. 
Dose 
52.5 
[2.1] 
9.8 
[1.95]
23.1 
[1.93] 79.3 
25.6 
[1.97] 80.6 
29.7 
[1.98] 83.7 
Avg. 
Dose 
6.7 
[0.27] 
0.8 
[0.15]
1.8
[0.15] 9.4 
1.8
[0.14] 9.3 
1.8 
[0.12] 9.3 
Heart 
Max. 
Dose 
50.5 
[2.02] 
6.1 
[1.22]
14.1 
[1.17] 66.8 
14.6 
[1.13] 66.3 
18.7 
[1.25]
61.0
Avg. 
Dose 
2.9 
[0.12] 
0.3 
[0.06]
0.7
[0.06] 4.0 
0.7
[0.05] 3.9 
0.6 
[0.04]
3.9
Esoph. 
Max. 
Dose 
52.5 
[2.1] 
6.0 
[1.19]
15.8 
[1.32] 74.2 
13.0
[1.0]
71.5 
 
9.9 
[0.66]
68.3
Avg. 
Dose 
11.5 
[0.46] 
0.9 
[0.17]
2.2
[0.18] 14.6 
2.1
[0.16]
14.5 
 
1.6 
[0.11]
14.0
N.O.S. 
Max. 
Dose 
52.5 
[2.1] 
10.5 
[2.1]
25.2
[2.1] 88.2 
27.3
[2.1] 90.3 
31.5 
[2.1]
94.5
Avg. 
Dose 
5.2 
[0.21] 
0.7 
[0.14]
1.6
[0.14] 7.5 
1.7
[0.13] 7.6 
1.8 
[0.12]
7.6
Spinal 
Cord 
Max. 
Dose 
7.2 
[0.29] 
2.3 
[0.45]
5.3
[0.44] 11.2 
3.6
[0.27] 9.0 
1.6
[0.1]
8.0
Avg. 
Dose 
1.1 
[0.04] 
0.2 
[0.03]
0.4
[0.03] 1.6 
0.5
[0.04] 1.7 
0.3 
[0.02]
1.5
# of Fractions Given 25 5 12 42 13 43 15 45
 
                                                            
11 The fraction size doses are given in brackets below the cumulative doses. PTV2 represents the 
secondary target. “N.O.S.” is abbreviation of “Not Otherwise Specified” tissue. 
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Appendix J12: Detailed Biological Data Information for Two Base Cases 
Tumor 
Regions 
Possible 
SUV Range 
First Base Case: Input 
Values 
Second Base Case: Input 
Values 
 SUV pO2 (mmHg) OMF SUV 
pO2 
(mmHg) OMF
Red 5.75-7.00 6.5 7.4 0.82 6.7 5.1 0.77 
Yellow 5.00-5.75 5.2 12.1 0.88 5.2 12.1 0.88 
Green 3.50-5.00 3.6 14.7 0.91 3.6 14.7 0.91 
Light 
Blue 2.00-3.50 2.5 17.5 0.92 2.5 17.5 0.92 
Dark 
Blue 0.00-2.00 0.25 46.6 0.98 0.25 46.6 0.98 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                            
12 SUV denotes Standardized Uptake Value, OMF denotes Oxygen-Modification Factor, pO2 
denotes Oxygen Tension 
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Appendix K13: Physical and Biological Optimization Results for the Head and Neck Base Case 
1 (“bDose” refers to biological dose, “pDose” refers to physical dose) 
Structure 
Dose Statistics 
(Gy) 
Physically 
Optimized Plan 
with 0.9 Physical 
Homogeneity 
Biologically 
Optimized Plan 
with 0.9 Physical 
Homogeneity 
Biologically 
Optimized Plan 
with 0.9 
Biological 
Homogeneity 
Total Total Total 
Primary 
Target 
Max. bDose 86.6 [2.22] 86.4 [2.27] 77.5 [2.04] 
Min. bDose 66.9 [1.71] 68.4 [1.8] 69.7 [1.84] 
Avg. bDose 78.9 [2.02] 78.5 [2.07] 74.5 [1.96] 
Primary 
Target 
Max. pDose 88.5 [2.27] 88.2 [2.32] 88.9 [2.34] 
Min. pDose 79.6 [2.04] 79.4 [2.09] 74.9 [1.97] 
Avg. pDose 85.0 [2.18] 84.6 [2.23] 80.4 [2.11] 
Target1 
Max. Dose 88.5 [2.27] 88.2 [2.32] 87.6 [2.30] 
Min. Dose 70.2 [1.8] 68.4 [1.80] 68.4 [1.8] 
Avg. Dose 78.5 [2.01] 77.9 [2.05] 76.3 [2.01] 
Target2 
Max. Dose 88.5 [2.27] 88.2 [2.32] 87.6 [2.3] 
Min. Dose 70.2 [1.8] 68.4 [1.80] 68.4 [1.8] 
Avg. Dose 76.5 [1.96] 75.3 [1.98] 75.5 [1.99] 
Target3 
Max. Dose 88.5 [2.27] 88.2 [2.32] 87.6 [2.30] 
Min. Dose 64.3 [1.65] 62.7 [1.65] 62.7 [1.65] 
Avg. Dose 73.8 [1.89] 72.7 [1.91] 72.7 [1.91] 
Mandible 
Max. Dose 72.0 [1.85] 72.0 [1.89] 72.0 [1.89] 
Avg. Dose 40.0 [1.03] 40.0 [1.05] 40.0 [1.05] 
Brainstem 
Max. Dose 58.0 [1.49] 58.0 [1.53] 58.0 [1.53] 
Avg. Dose 34.1 [0.87] 33.4 [0.88] 29.6 [0.78] 
Spinal 
Cord 
Max. Dose 50.0 [1.28] 50.0 [1.32] 50.0 [1.32] 
Avg. Dose 18.5 [0.47] 17.0 [0.45] 18.5 [0.49] 
Not 
Otherwise 
Specified 
Max. Dose 80.0 [2.05] 79.8 [2.10] 79.8 [2.10] 
Avg. Dose 25.7 [0.66] 25.5 [0.67] 25.2 [0.66] 
# of Fractions Given 39 38 38 
 
                                                            
13 The fraction size doses are given in brackets besides the cumulative doses. 
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Appendix L14: Physical and Biological Optimization Results for the Head and Neck Base Case 2 
(“bDose” refers to biological dose, “pDose” refers to physical dose) 
Structure 
Dose Statistics 
(Gy) 
Physically 
Optimized Plan 
with 0.8 Physical 
Homogeneity 
Biologically 
Optimized Plan 
with 0.8 Physical 
Homogeneity 
Biologically 
Optimized Plan 
with 0.8 
Biological 
Homogeneity 
Total Total Total 
Primary 
Target 
Max. bDose 95.9 [2.52] 96.5 [2.54] 84.7 [2.23] 
Min. bDose 63.5 [1.67] 64.8 [1.7] 67.8 [1.78] 
Avg. bDose 81.6 [2.15] 78.8 [2.07] 75.2 [1.98] 
Primary 
Target 
Max. pDose 97.9 [2.58] 98.6 [2.59] 98.0 [2.58] 
Min. pDose 78.4 [2.06] 78.9 [2.08] 69.8 [1.84] 
Avg. pDose 88.1 [2.32] 85.2 [2.24] 81.3 [2.14] 
Target1 
Max. Dose 97.9 [2.58] 98.6 [2.59] 95.7 [2.52] 
Min. Dose 68.4 [1.80] 68.4 [1.80] 68.4 [1.80] 
Avg. Dose 79.4 [2.09] 78.7 [2.07] 77.2 [2.03] 
Target2 
Max. Dose 97.9 [2.58] 94.3 [2.48] 95.7 [2.52] 
Min. Dose 68.4 [1.80] 68.4 [1.80] 68.4 [1.80] 
Avg. Dose 76.5 [2.01] 76.6 [2.01] 76.1 [2.00] 
Target3 
Max. Dose 97.9 [2.58] 98.6 [2.59] 95.7 [2.52] 
Min. Dose 62.7 [1.65] 62.7 [1.65] 62.7 [1.65] 
Avg. Dose 73.9 [1.94] 74.2 [1.95] 72.9 [1.92] 
Mandible 
Max. Dose 72.0 [1.89] 72.0 [1.89] 72.0 [1.89] 
Avg. Dose 40.0 [1.05] 40.0 [1.05] 40.0 [1.05] 
Brainstem 
Max. Dose 58.0 [1.53] 58.0 [1.53] 58.0 [1.53] 
Avg. Dose 28.5 [0.75] 27.9 [0.73] 27.0 [0.71] 
Spinal Cord 
Max. Dose 50.0 [1.32] 50.0 [1.32] 50.0 [1.32] 
Avg. Dose 19.2 [0.5] 16.2 [0.43] 15.6 [0.41] 
Not 
Otherwise 
Specified 
Max. Dose 79.8 [2.10] 79.8 [2.10] 79.8 [2.10] 
Avg. Dose 23.9 [0.63] 25 [0.66] 24.1 [0.63] 
# of Fractions Given 38 38 38 
 
                                                            
14 The fraction size doses are given in brackets besides the cumulative doses. 
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Appendix M: Sensitivity of TCP to the Change in Standardized Uptake Value (SUV) 
 
Throughout the computational experiments on biology, the sensitivity of tumor control 
probability (TCP) to the change in the standardized uptake value (SUV) was realized. This is 
illustrated in Table M.1 where the cumulative tumor biological and physical dose statistics as 
well as the achieved TCP are given for both physical and biological plans computed for second 
and third base cases. The third base case differs from the second base case by having higher 
hypoxia in red region (SUV=6.8 vs. 6.7). As the results in Table M.1 show, although the average 
biological doses in physical (biological) plans are very similar between second and third base 
case, the reduction in the minimum biological dose (63.5 Gy vs. 58.6 Gy for physical plans, 64.8 
Gy vs. 59.8 Gy for biological plans) has reduced the TCPs from 0.63 to 0.05 and 0.70 to 0.20 for 
physical and biological plans, respectively. The significant decline in TCP relative to the change 
in SUV shows the sensitivity of the TCP function. However, the improvement in TCP obtained 
by biological plan still holds for the third base case (from TCP=0.05 to TCP=0.20).      
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Table M.1: Illustrating the Sensitivity of Tumor Control Probability to the Change in 
Standardized Uptake Value (SUV) by Comparing Physical and Biological Plans between Second 
and Third Base Cases (Numbers in bold are referred in the text.) 
Cumulative Tumor 
Dose Statistics 
Second Base Case (SUV=6.7 
for Red Region) 
Third Base Case (SUV=6.8 for 
Red Region) 
Physically 
Optimized 
Plan with 0.8 
Tumor 
Physical Dose 
Homogeneity 
Biologically 
Optimized 
Plan with 0.8 
Tumor 
Physical Dose 
Homogeneity 
Physically 
Optimized 
Plan with 0.8 
Tumor 
Physical Dose 
Homogeneity 
Biologically 
Optimized 
Plan with 0.8 
Tumor 
Physical Dose 
Homogeneity 
Max. bDose (Gy) 95.9          96.5 95.9 96.5 
Min. bDose (Gy)  63.5 64.8 58.6 59.8 
Avg. bDose (Gy)  81.6 78.8 81.4 78.5 
Max. pDose (Gy) 97.9 98.6 97.9 98.6 
Min. pDose (Gy) 78.4 78.9 78.4 78.9 
Avg. pDose (Gy) 88.1 85.2 88.1 85.2 
Tumor Control 
Probability (TCP) 0.63  0.70 0.05 0.20 
 
For the physical plan enforcing 0.8 physical homogeneity, Figure M.1 shows how its TCP 
changes relative to the different values of red region OMF. The graph shows that the TCP 
becomes sensitive when red region’s OMF value falls below 0.8. The reason behind higher 
sensitivity at lower OMF values is due to the mathematical function of the surviving fraction. 
After leaving the re-population effect term off the surviving fraction equation (5.15) in Section 
5.2.4 due to being independent of OMF, the surviving fraction formula only includes the cell 
killing effect which has the form of 1/ex. This function decreases slower as x increases. Since the 
higher values of OMF (≥0.8) would correspond to higher values of x, the change in the higher x 
values wouldn’t change the surviving fraction as much the change in the lower x values 
(corresponding to lower OMF values) would create. As a result, the change in the lower OMF 
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values would change the surviving fraction with a higher rate resulting in a more significant 
change in TCP.       
 
 
Figure M.1: Tumor Control Probability Relative to the Change in Oxygen-Modification Factor 
of Red Region  
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